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ABSTRACT 
 
MICHAEL DURANDO: Novel Mechanisms through which Translesion Synthesis Protects 
Genome Integrity 
 (Under the direction of Cyrus Vaziri, Ph.D.) 
 
 
Exposure to ubiquitous environmental carcinogens, such as polycyclic aromatic 
hydrocarbons and UV light, is a major cause of human disease. It is well accepted that 
genetic mutations are an important step in the development of cancer. It has become clear 
that such mutations are introduced in part by error-prone DNA polymerases. In response to 
many environmental genotoxins, eukaryotic cells have evolved alternative methods of 
replicating damaged DNA via the Translesion DNA synthesis (TLS) Polymerases, consisting 
of DNA Polymerase eta (Polη), DNA Polymerase kappa (Polκ), DNA Polymerase iota (Polι), 
and Rev1. TLS is a DNA damage tolerance mechanism that uses low-fidelity DNA 
polymerases to replicate damaged DNA. The inherited cancer-propensity syndrome 
Xeroderma Pigmentosum Variant (XPV) results from error-prone TLS of UV-damaged 
DNA. TLS is initiated when the Rad6/Rad18 complex monoubiquitinates PCNA, but the 
basis for recruitment of Rad18 to PCNA is poorly understood. This dissertation studies 
several aspects of regulatory mechanisms that contribute to the damage-induced activation of 
Rad18 E3 ligase activity at PCNA. First, we report a novel role for Pol η, the XPV gene 
product that is mutated in XPV, in targeting Rad18 to PCNA to initiate TLS. Using structure-
function analyses and immunofluorescence microscopy, we identified a C-terminal domain 
of Polη that physically bridges Rad18 and PCNA to facilitate redistribution of Rad18 to 
  
 
iii 
stalled replication forks and promote PCNA monoubiquitination. This scaffold function is 
unique to Polη among Y-family TLS polymerases and dissociable from its catalytic activity. 
Importantly, XPV cells expressing full-length, catalytically inactive Polη exhibit increased 
recruitment of error-prone TLS Polymerases after UV irradiation, indicating that maintaining 
the bridging function of Polη in the absence of its catalytic activity greatly predisposes to 
mutagenesis. These findings define a molecular basis for TLS pathway activation and 
provide a new mechanism for mutagenesis and genomic instability in XPV individuals. Next, 
this dissertation reports novel mechanisms of regulating TLS via stress-activated protein 
kinase (SAPK) phosphorylation of Rad18 and via Chk1-dependent phosphorylation events. 
Finally, this dissertation presents data indicating that TLS is involved in the tolerance of 
oncogene-induced replication stresses and potentially oncogene-induced mutagenesis. 
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CHAPTER 1 
 
INTRODUCTION  
 
1. UV light, benzo[a]pyrene, and environmental carcinogenesis 
 
UV light and polycyclic aromatic hydrocarbons (PAHs) are ubiquitous 
environmental mutagens and carcinogens. Solar UV light is omnipresent and is a 
major cause of morbidity worldwide.1,2 Solar UV radiation is divided into three types: 
UVC, UVB, and UVA (Table 1-1).3 UV radiation causes DNA damage in a manner 
inversely proportional to wavelength.4 Solar radiation below 290 nm carries the 
highest energy and is most detrimental to DNA and other biomolecules but is 
primarily absorbed by stratospheric ozone. Approximately 90% of the UV radiation 
that traverses atmospheric ozone is relatively low-energy UVA.3 
 
Table 1.1. Properties of solar ultraviolet (UV) radiation 
UV radiation Wavelength (nm) Energy (eV) % reaching earth surface 
UVC (<280) >4.4 0 
UVB (280-315) 3.9-4.4 10 
UVA (315-400) 3.1-3.9 90 
 
 
UV radiation causes DNA damage through different mechanisms depending 
on wavelength.5 The genotoxic effects of UVC and UVB are predominantly due to 
absorption by adjacent pyrimidine moieties in DNA, causing fusion of their double 
bonds to form cyclobutane pyrimidine dimers (CPDs) and also to a lesser extent 6-4 
pyrimidine-pyrimidone photoproducts (6-4-PPs) (Figure 1-1).6 UV-induced cell 
killing correlates directly with the induction of DNA lesions up to about 313 nm, but 
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at greater wavelengths (UVA), cell killing remains high while the relative number of 
DNA lesions decreases. In fact, irradiation at 385 nm and higher still induces high 
relative cytotoxicity, even when CPDs are virtually undetectable,7 indicating that 
DNA damage mechanisms other than CPDs or 6-4PPs contribute to UVA-induced 
killing at these wavelengths. Consistently, depletion of glutathione to cause oxidative 
stress leads to a many-fold increase in UVA-induced DNA mutations but no change 
in UVB-induced mutations, indicating that the genotoxic effects of UVA are 
predominantly due to production of Reactive Oxygen Species (ROS), such as 
hydrogen peroxides and hydroxyl radicals.8 Thus, UVC and UVB induce mutations 
primarily via direct modification of DNA whereas UVA is mutagenic primarily via 
ROS.  
 
Figure 1-1. Schematic representation of major UV-induced DNA lesions. 
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PAHs are a major source of environmental pollutant that are produced 
primarily through the processing and consumption of coal and crude oil but also 
through combustion of wood and tobacco products.9 Human exposure to PAHs has 
been associated with increased cancer risk, and many PAHs are tumorigenic in 
animal models.9 PAHs such as Benzo[a]pyrene (B[a]P) require activation to 
electrophilic metabolites to exert mutagenic or carcinogenic effects. In vivo, such 
PAHs are metabolized in mammalian cells by cytochrome P450s to generate the 
highly reactive and mutagenic metabolites. B[a]P, for example is metabolized to its 
highly reactive form BPDE, which binds covalently to genomic DNA to form bulky 
adducts at the N2 position of guanine (Figure 1-2).10,11 Such bulky adducts resemble 
UV-induced DNA lesions and induce mutations and cell killing via similar 
mechanisms, although PAHs illicit distinct cellular responses as well.12  
 
Figure 1-2. Metabolic processing of Benzo[a]pyrene to the genotoxin BPDE, which covalently 
binds to deoxyguanine. 
 
Mutations are a fundamental step in the progression of many human diseases, 
including cancer, and propagation of cells that have acquired mutations in oncogenes 
or tumor suppressor genes contributes to multi-step carcinogenesis. Mutations can be 
introduced via numerous mechanisms, such as replication and repair errors, 
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depurination or deamination, and endogenous or environmental mutagens.13 DNA 
harboring bulky DNA lesions, such as CPDs or dG-BPDE, adopts a distorted 
conformation that impedes normal replication. The presence of such damaged DNA is 
strongly correlated with the acquisition of mutations. For example, the location of 
UV- or BPDE-induced mutations in the p53 gene correlates strongly with hotspots of 
CPDs and BPDE target sites, respectively.14, 15 Thus, replication or repair of DNA 
containing CPD and dG lesions carries a high risk of introducing mutations.14 
 
2. DNA Damage Tolerance and Trans-Lesion Synthesis (TLS)  
 
Living cells are continually exposed to endogenous and environmental DNA 
damaging agents, such as UV light and BPDE. It has been estimated that cells 
encounter approximately 10,000 DNA lesions/day16. Such an onslaught of DNA 
damage poses a major threat to genetic instability, and cells have evolved numerous 
mechanisms of tolerating it. Major DNA repair pathways in human cells include base 
excision repair (BER), nucleotide excision repair (NER), homologous recombination, 
non-homologous end-joining, Fanconi Anemia, and translesion synthesis (TLS)17. 
Deficiencies in any of these pathways compromises genetic stability, as evidenced by 
their associated cancer propensity syndromes (Table 1-2). 
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Table 1-2. Major DNA repair pathways and associated cancer 
propensity syndromes. 
Pathway Syndrome Deficient protein 
NER XP many 
BER Various cancers OGG1, XRCC118 
HR Breast, ovary cancer Brca1, Brca219 
NHEJ LIG4 syndrome Ligase IV20 
FA Fanconi Anamia 15 FANCs21 
TLS XPV Poleta 
 
 
Each of these DNA repair pathways protect against the deleterious effects of 
DNA damage. With regard to UV light and PAHs, CPDs and BPDE adducts greatly 
predispose to mutagenesis. Replicative polymerases replicate undamaged DNA with a 
high processivity and fidelity, but they are unable to replicate past UV- and BPDE-
induced DNA lesions. Instead, replicative polymerases stall after encountering such 
DNA lesions, as the tight catalytic active site of a replicative polymerase is incapable 
of accommodating such bulky DNA-distorting adducts (Figure 1-3). Stalling of the 
replicative polymerase causes uncoupling of the replication fork, in which the MCM-
containing helicase complex continues unwinding DNA after the polymerase ceases 
replication (Figure 1-4). This leads to long stretches of single-stranded DNA that is 
rapidly coated by Replication Protein A (RPA), thus initiating a series of signaling 
cascades that halts replication and turns on DNA repair pathways (see Checkpoints 
section). 
  
 
6 
 
Figure 1-3. Diagram of a processive polymerase that has stalled upon encountering a bulky DNA 
adduct (yellow) in its active site.  
 
Unlike other DNA repair pathways that do not necessarily distinguish between 
the nature of DNA damage, the translesion synthesis (TLS) pathway of DNA damage 
tolerance is specifically directed toward replication-stalling bulky DNA adducts, such 
as those induced by UV light and BPDE. TLS utilizes a group of low-processivity, 
low-fidelity polymerases (compared to replicative polymerases) that are capable of 
replicating past bulky DNA adducts. Bypass of bulky DNA adducts is performed 
primarily by a specialized group of four DNA polymerases called the Y-family 
Polymerases (Y Pols),22 consisting of DNA Polymerase eta (Polη)23, DNA 
Polymerase kappa (Polκ),24 DNA Polymerase iota (Polι),25 Rev1.26,27 
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Figure 1-4. Uncoupling of the replication fork and helicase after encountering a bulky adduct 
DNA lesion. 
 
In response to bulky DNA adducts like CPDs, these polymerases are recruited 
to replication forks where they interact with proliferating cell nuclear antigen, PCNA, 
a homotrimeric replication processivity factor to which DNA polymerases bind as 
they replicate DNA. Polη, Polκ, and Polι contain highly conserved PCNA Interacting 
Peptide domains (PIP boxes) that facilitate physical interaction with PCNA,28 
whereas Rev1 interacts with PCNA via a BRCT domain.29 For TLS to occur, a Y-
family polymerase must switch places with the replicative polymerase that has stalled 
upon encountering a bulky adduct (Figure 1-5a).30,31 The mechanisms dictating this 
polymerase switch and the selection of the appropriate polymerase are poorly 
understood, but engagement of the appropriate polymerase with PCNA facilitates 
replicative bypass of the bulky adduct (Figure 1-5b). Such replicative bypass of 
bulky adducts is called TLS or lesion bypass. 
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Figure 1-5.  High fidelity replicative polymerase is replaced by a low-fidelity Y-family 
Polymerase (A) to perform TLS across the bulky adduct DNA lesion (B). 
 
TLS across replication-stalling lesions protects against DNA breakage in the 
wake of uncoupled replication forks. After replicative polymerases stall upon 
encountering bulky DNA adducts, re-priming of the leading strand downstream of the 
stalled polymerase allows replication to continue but leaves ssDNA gaps between the 
site of re-priming and the stalled polymerase.32 TLS facilitates replication restart at 
the site of the stalled polymerase and subsequent completion of replication 
throughout these ssDNA gaps; loss of TLS and checkpoints (see below) increases the 
number and persistence of such ssDNA gaps,32, 33 which predisposes to chromosome 
instability.34 
TLS is thus a crucial mechanism of preserving genomic integrity in the wake 
of environmentally induced DNA damage. However, the ability of TLS Pols to 
replicate past bulky adducts is counterbalanced by their reduced fidelity, 
incorporating errors at a rate of approximately 1 per 103 bp, substantially higher than 
replicative Pols, such as Polδ.35,36,37 This relatively low fidelity of TLS Pols leads 
directly to the introduction of mutations in the genome. 
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3. TLS and mutagenesis  
The existence of error-prone DNA repair pathways was first uncovered in 
early studies on bacterial mutants that were found to be nearly resistant to UV-
induced mutations.38 The first genes associated with UV-induced mutagenesis were 
recA and laxA in E. coli, which, when deleted, eliminated a global DNA damage 
response (SOS response) and also suppressed UV mutability38. Over 30 genes have 
since been linked to the DNA damage-inducible SOS response in bacteria, but the 
mutagenic portion of SOS is linked almost exclusively to those genes involved in 
TLS39. First discovered in screens of E. coli mutants that are not mutable by UV 
light,40, 41 members of the UmuC/DinB family were found to exhibit polymerase 
activity across DNA lesions.39 Specifically, Pol V in E. coli, consisting of UmuC and 
UmuD’2, is capable of replicating across UV-induced lesions such as CPDs42 
whereas DinB1 (Pol IV) can replicate across bulky adducts at the N2 position of 
guanine.43 Eukaryotic homologues of the SOS genes were later discovered. In S. 
cerivisiae, the TLS activities of E. coli Pol V are performed by Rad30, which 
processes UV-induced lesions,44 and Rev1, which processes abasic sites and drives 
mutagenesis.45 In humans, these TLS activities are performed by the Y-family 
polymerases: Polη,46 (homologue of E. coli Pol V and yeast Rad30), Rev147 
(homologue of E. coli Pol V and yeast Rev1), Polκ48 (homologue of E. coli DinB1; 
no yeast homologue), and Polι49 (originally called Rad30B, no yeast or bacterial 
homologues).  
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Much research has been dedicated to the nature and the significance of low-
fidelity replication by TLS polymerases. Important concepts of debate involve (i) 
whether the infidelity is “beneficial” or “deleterious” for the cell and (ii) whether the 
infidelity is accurately defined as “error-prone.” The following discussion will 
address both of these points. 
The infidelity of TLS Pols is attributed to several structural features of Y-
family polymerases that differ substantially from replicative polymerases. Although 
the Y-family polymerases share almost no sequence homology with replicative DNA 
polymerases, they maintain structural similarities common to replicative polymerases, 
such as the classic right-hand polymerase fold that wraps around a DNA template 
(Figure 1-6) and highly conserved aspartate and glutamate residues in the active sites 
that coordinate magnesium ions and stabilize incoming dNTPs.50, 51 These 
similarities, common to nearly all polymerases, are perhaps not surprising considering 
the replicative capabilities of the TLS polymerases, but several important structural 
and functional differences from replicative polymerases are responsible for their 
inaccurate replicative potential and in turn their important roles in error-prone 
replication, mutagenesis, and genome stability. 
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Figure 1-6.  Crystal structure of S. cerevisiae Rad30 in complex with DNA showing the right-
hand conformation consisting of palm, thumb and finger domains common to all DNA 
polymerases, as well as the little finger domain, or PAD, unique to Y-family polymerases.50 
 
Key among these differences is their lack of 3’ to 5’ exonuclease proofreading 
activity that is common to all replicative polymerases and that removes mismatched 
bases.50 Lack of such proofreading capabilities allows TLS Pols to continue 
replication even after insertion of the incorrect base, whereas replicative polymerases 
can remain stalled in futile insertion-excision cycles.52 
Next, although Y-family polymerases contain palm, thumb, and finger 
domains analogous to replicative polymerases, structural nuances that are common to 
the Y-family Pols but different from replicative pols impart unique functional 
characteristics that directly impact their processivity and accuracy (Figure 1-6).52 The 
finger domain in Y-family pols uniquely contains a so-called polymerase-associated 
domain (PAD), also called a little finger domain, which is normally loose and flexible 
but adopts a stable conformation after engagement with the cognate lesion on DNA.53 
The PAD thus determines the lesion specificity of the Y-family Pols, allowing certain 
Pols to replicate across their cognate lesion with relative accuracy. Polη and Polκ, for 
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example, perform TLS across CPDs and dGs, respectively, with relatively higher 
accuracy compared to replication across undamaged templates or other lesions. The 
PAD also contributes to catalytic efficiency and the mutational spectra.53 Compared 
to replicative Pols, the palm, thumb and finger domains of Y-family Pols hold DNA 
with a more “open” grip, resulting in a dramatically reduced processivity.50 
Regarding replicative fidelity, the active sites of Y-family polymerases are 
larger and more open than in replicative DNA polymerases, they form fewer contacts 
with template and nascent DNA strands, and they fail to exhibit the “induced-fit” 
conformational changes that drive dNTP specificity in replicative polymerases.50 All 
of these characteristics combined yield a family of polymerases that, compared to 
replicative polymerases, have (i) reduced fidelity, (ii) reduced processivity, (iii) 
greater flexibility in accommodating aberrant DNA structures, (iv) unique mutational 
spectra, and (v) favored cognate lesions (Table 1-3). These properties have important 
implications for both the tolerance of replication-stalling DNA lesions and the genesis 
of mutations. 
Table 1-3. Properties of Y-family Pols in comparison to 
replicative Pols. 
Property Y-family Pols relative to Replicative Pols Phenotypic outcome 
Fidelity  Low Mutagenesis 
Processivity Low Short-lived activation 
Active site  Loose, non-discriminatory Mutagenesis 
Preferred 
template Lesion specific 
Mutagenic for non-
preferred lesion 
 
Regarding the discussion of whether the Y-family polymerases are beneficial 
or deleterious for a cell, one must consider the context in which they are utilized. 
When replicative polymerases stall after encountering bulky DNA lesions, persistent 
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uncoupling of replication forks can lead to fork collapse, single-strand DNA breaks, 
and double-strand breaks. Lesion bypass after replacement of the replicative Pol with 
a TLS Pol can be considered beneficial as it prevents the deleterious effects of DNA 
breaks by allowing replication to continue. Of note, a single unrepaired double strand 
break is sufficient to mediate cell death.54 However, TLS can also be considered 
deleterious if the wrong polymerase is utilized for a specific lesion, thus promoting 
mutagenesis. For example, use of Polκ, whose preferred lesion is a bulky adduct at 
dG, to bypass a CPD instead of Polη (whose preferred lesion is a CPD), will be 
highly mutagenic, whereas use of Polη to bypass a CPD will be relatively accurate. 
Experiments in human cells have in fact demonstrated Polη-mediated error-free TLS 
across CPDs and highly mutagenic TLS across CPDs by Polκ.55 It is critical, 
therefore, for cells to select the proper polymerase for the proper lesion. 
 Activation of the TLS Pols in the absence of damage, use of the wrong TLS 
polymerase, or absence of the proper polymerase after acquisition of DNA damage 
conferring its preferred lesion will all predispose to mutagenesis. Such scenarios 
highlight the unique and often confusing aspect of the TLS pathway: the TLS 
Polymerases are absolutely necessary to prevent genetic instability, but their aberrant 
activation will unequivocally lead to genetic instability. In other words, the TLS Pols 
must be activated only in response to DNA damage and the cell must ensure that only 
the correct polymerase is used for the right type of damage. The consequences of 
failed TLS regulation is best exemplified by the cancer propensity syndrome 
Xeroderma Pigmentosum Variant, in which Polη is functionally absent, leading to 
mutagenic replication of UV-damaged DNA by inappropriate TLS Polymerases (see 
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XPV section). The properties of TLS Pols summarized in Table 1-3 and the 
phenotypic outcome of aberrant TLS activity demonstrate the importance of proper 
regulation of TLS. The molecular mechanisms that regulate TLS are still poorly 
understood and are also largely the focus of this dissertation. 
One final important distinction of TLS involves the replication past damaged 
bases without removing the damage. Whereas DNA repair processes such as BER 
and NER remove damaged bases from the genome, TLS does not actually repair 
damaged DNA. Rather, it promotes tolerance of damaged DNA by allowing the 
continuation of replication without actually removing the damage. TLS thus promotes 
genomic stability primarily by preventing the catastrophic consequences of 
replication fork collapse, not by actually repairing or removing damaged DNA. 
 
4. Checkpoints and the DDR  
 
Central to the proper regulation of TLS is a cell’s ability to detect and respond 
to DNA damage. DNA damage responses are activated by a cascade of intracellular 
signals that are elicited by the recognition of DNA damage. These signals, called 
checkpoints, utilize DNA damage sensors, signal transducers, and effector proteins to 
coordinate processes of DNA repair. Generally, sensor proteins (e.g. the MRN and 9-
1-1 complexes) detect DNA damage on chromatin and activate signal transducers 
(e.g. ATM/ATR and Chk1/Ch2), which amplify the checkpoint signal to activate 
proximal and distal effector proteins (e.g. BRCA1). Such effector proteins are 
recruited to chromatin, where they facilitate damage repair or tolerance at the site of 
DNA damage or promote cell cycle stalling via degradation or inactivation of 
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replication cell cycle proteins such as cyclin-dependent kinases. Checkpoints thus 
coordinate cell cycle progression with genome maintenance, helping ensure that the 
cell cycle does not proceed if genome integrity is compromised. 
 
Figure 1-7. Replication-stalling lesions, such as those induced by UV light and BPDE, uncouple 
the replication fork forming long stretches of single-stranded DNA, which is coated by RPA. 
RPA recruits ATR, which activates ATRIP to phosphorylate Chk1, which then 
simultaneously turns on DNA damage tolerance processes and turns off normal replication.  
 
The S-phase checkpoint response to replication stress is typically divided into 
two main pathways: an ATM-mediated checkpoint that responds to DNA double-
strand breaks and an ATR-mediated response to stalling and uncoupling of replication 
forks.56, 57 However, much cross-talk exists between the two pathways; over 700 
proteins have been identified as targets of damage-induced phosphorylation by ATM 
and ATR, almost all of which are involved in DNA damage repair or checkpoints and 
many of which are phosphorylated by both pathways.58 
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Double-strand breaks are processed within cells after recognition by the 
Mre11-Rad50-Nbs1 (MRN) complex. ATM is rapidly recruited to these DSBs via 
physical interactions between the HEAT motifs in ATM and the C-terminus of 
Nbs1.59 Activated ATM phosphorylates a variety of targets, including KAP1, which 
induces chromatin relaxation,60 and Chk2, which promotes cell cycle arrest. Once 
activated by ATM, Chk2 phosphorylates Cdc25A, a dual-specificity 
threonine/tyrosine phosphatase that promotes cell cycle progression by activating 
cyclin dependent kinase complexes, such as CDK2-Cyclin A, via 
dephosphorylation.61 Chk2-mediated phosphorylation of Cdc25A targets Cdc25A for 
ubiquitin-dependent degradation, thus decreasing activation of CDKs and inhibiting 
cell cycle progression.62 
Regarding DNA damage from UV light and PAHs, current models depict that 
damage-induced stalling of replication forks leads to uncoupling of the helicase and 
polymerase, yielding long stretches of single-stranded DNA (ssDNA)63, 64 (Figure 1-
7). ssDNA is rapidly coated by RPA, a heterotrimeric complex consisting of 70, 30, 
and 14 kDa monomers, RPA1, RPA2, and RPA3, respectively. In addition to its high 
affinity to ssDNA, RPA also binds to many other proteins involved in DNA repair, 
including the checkpoint signal transducer ATR-interacting protein (ATRIP). ATRIP 
binds to the N-terminus of RPA1 and recruits its binding partner, ATR, to 
chromatin65-67 Once docked at RPA-coated ssDNA, ATR-ATRIP is activated by the 
presence of Rad9-Rad1-Hus1 (9-1-1), a clamp that encircles DNA and recruits 
BRCT-containing proteins, such as TopBP1, to chromatin.66 TopBP1 contains an 
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ATR activation domain and strongly stimulates ATR kinase activity to initiate a 
series of signaling cascades that amplify the DNA damage response.68, 69 
One important signal transducer downstream of ATR is the S-phase kinase 
Chk1. ATR-mediated phosphorylation of Chk1 at serines 317 and 345 activates Chk1 
via two mechanisms: uncovering of its N-terminal kinase domain70 and release of 
inactive chromatin-bound Chk1 to redistribute to centrosomes and block mitotic 
entry.71 Like Chk2, activated Chk1 targets Cdc25A for degradation to block cell cycle 
progression and suppress origin firing via inhibition of the cyclin-dependent kinase 
Cdk2.72 Chk1 also blocks cell cycle progression through Cdc25A-independent 
mechanisms involving via direct phosphorylation of Dbf4.73 Phosphorylation of Dbf4 
is thought to promote removal of Dbf4 from chromatin and inhibit its binding to 
Cdc7, thus inhibiting the kinase activity of the Dbf4/Cdc7 complex.73 Inhibition of 
Cdc7 decreases loading of the MCMs to the pre-replicative complex74 and also blocks 
Cdc45 loading75 and interaction between Cdc45 and MCM7,76 thereby inhibiting 
initiation of DNA synthesis at origins of replication. 
Although ATM and ATR are frequently described as independent responses to 
double-strand breaks and stalled replication forks, respectively, extensive cross-talk 
exists between the two pathways. For example, DSBs can lead to ATR activation in a 
manner that is dependent on ATM,77 whereas UV-induced replication stalling can 
activate ATM via ATR-mediated phosphorylation.78 Similarly, ionizing radiation can 
cause ATM- and NBS1-dependent phosphorylation of Chk1 through ATR-
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independent mechanisms.79 Therefore, ATM and ATR function in parallel but also in 
concert to mediate checkpoint responses to DNA breaks and fork-stalling lesions. 
Numerous links between checkpoints and TLS have been demonstrated. First, 
damage-induced Chk1 activation leads to the phosphorylation-mediated activation of 
Cdc7 (though Chk1 does not directly phosphorylate Cdc7), which itself 
phosphorylates Rad18 to drive Rad18-Polη binding and help promote tolerance of 
UV damage (see section on Rad18 and TLS).80 Next, Chk1 is reported to facilitate 
maximal damage-induced PCNA monoubiquitination, albeit via kinase-independent 
mechanisms.81 Altogether, DNA damage-induced checkpoints contribute to TLS-
mediated DNA damage tolerance by both stalling replication to allow for TLS to 
occur and through direct stimulation of TLS via Chk1. 
 
5. TLS activation and Rad18 and DNA damage tolerance 
pathways  
Although the precise mechanisms that regulate activation of TLS remain 
poorly understood, it is generally accepted that TLS activation depends in large part 
upon physical docking of replicative or TLS polymerases with the homotrimeric 
replication factor PCNA. Which polymerase interacts with PCNA is determined in 
large part by the post-translational modification of PCNA by Rad18. 
RAD18 is a highly conserved gene that was first identified in yeast in the same 
epistatis group as RAD6 on the basis of increased sensitivity of UV and ionizing 
radiation.82 Human Rad18 codes for a 495 amino acid protein with several important 
functional domains. These include an N-terminal RING-finger domain that mediates 
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catalytic activity and Rad6 binding (amino acids 26-64),83 a C-terminal Rad6 binding 
domain (amino acids 340-395),84 a Zinc finger domain that mediates accumulation at 
sites of DNA damage (amino acids 201-225),84 a SAP domain that promotes 
assembly at stalled replication forks (amino acids 248-284),85 a C-terminal Polη 
binding domain (amino acids 402-445),86 and a C-terminal nuclear localization signal 
(amino acids 488-494).85 
Rad18 is an E3 ubiquitin ligase that plays a central role in DNA damage 
tolerance by catalyzing the damage-induced monoubiquitination of PCNA.87 In 
conjunction with its E2 ubiquitin-conjugating enzyme and binding partner, Rad6, 
Rad18 redistributes to stalled replication forks after DNA damage, where it catalyzes 
the monoubiquitination of PCNA at lysine 164 (Figure 1-8).88,89 The Rad6-Rad18 
complex is highly selective for PCNA monoubiquitination, a signaling event that has 
important implications for many aspects of the DNA damage response. 
Rad18-mediated monoubiquitination of PCNA at lysine 164 serves as a signal 
to turn on both TLS and template switching. TLS is activated in part due to increased 
affinity of Y-family polymerases to monoubiquitinated PCNA compared to 
unmodified PCNA (see below). Template switching is an error-free post-replication 
repair process that is thus dependent on Rad18 for activation. Template switching is 
activated by HTLF/SHPRH-mediated (Rad5 in yeast) polyubiquitination of K164 that 
takes place only after Rad18-mediated K164 monoubiquitination.90 Rad18 thus 
stimulates both error-free (template switching) and error-prone (TLS) post-replication 
repair mechanisms through its catalytic activity at K164 on PCNA. 
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Rad18 also contributes to DNA damage tolerance through E3 ligase-
independent functions. In contrast to post-replication repair of fork-stalling lesions, 
Rad18 confers tolerance of double-strand breaks by promoting homologous 
recombination through physical interactions with Rad51C, a key protein in the initial 
steps of HR.91 Damage-induced Rad18-Rad51C interactions promote recruitment of 
Rad51 to DNA DSB, where Rad51 may begin strand invasion to initiate HR.92 This 
HR-promoting activity of Rad18 requires the RING and zinc finger domains but not 
the SAP or Rad6-binding domains. The RING domain of Rad18 facilitates physical 
interaction with Rad51C, and the zinc finger domain mediates Rad18-binding to 
ubiquitinated proteins at sites of DNA damage. These Rad18-binding proteins are 
ubiquitinated at DSBs by RNF8, another damage-inducible E3 ligase. Rad18 
recruitment to DSBs thus depends on RNF8-mediated ubiquitination events; Rad18 
appears to chaperone Rad51C to such DSB sites. Interestingly RNF8-mediated 
ubiquitination events seems necessary for recruitment of Rad18 to DSB sites but not 
stalled replication forks. Rad18 thus uses the same domains for entirely different 
functions (RING domain for PCNA monoubiquitination in TLS and for Rad51C 
recruitment in HR), thereby contributing to activation of distinct DNA damage 
tolerance pathways.  
 
6. TLS activation and Rad18  
As illustrated above, Rad18-mediated PCNA monoubiquitination serves as a 
signal to activate TLS at stalled replication forks. TLS requires replacement of stalled 
replicative polymerases with TLS polymerases capable of bypassing DNA lesions. 
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This switching mechanism is attributed to a higher affinity of TLS polymerases to 
monoubiquitinated PCNA compared to unmodified PCNA. In addition to their highly 
conserved PIP-boxes (and BRCT domain for Rev1), the Y-family polymerases 
contain ubiquitin-binding motifs (UBZ domains) that confer high-affinity binding to 
monoubiquitinated PCNA.93, 94 Replicative polymerases, conversely, display reduced 
affinity to monoubiquitinated PCNA. By creating a docking site on PCNA suitable 
for TLS Pol binding, it has been proposed that PCNA monoubiquitination by Rad18 
constitutes the basis for the engagement of TLS Pols with the replication machinery 
and in turn activation of TLS (Figure 1-8).95,96,97 Such a hypothesis is supported by 
the findings that TLS Pol mutants in which the UBZ domains have been mutated 
demonstrate reduced redistribution to stalled replication foci,94 that XPV cells 
complemented with UBZ-mutant Polη exhibit UV survival defects,93, 94 and that UV 
survival is compromised in knock-in PCNA mutants in which lysine 164 has been 
mutated to eliminate Rad18-mediated PCNA monoubiquitination.98 The reliance of 
TLS on PCNA monoubiquitination is not unanimously accepted, however, as other 
investigators have reported no UBZ-dependent effect of Polη on UV survival, 
redistribution to stalled replication forks, or in vitro TLS activity.99,100 
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Figure 1-8. Rad18-mediated PCNA monoubiquitination drives binding of TLS polymerases to 
PCNA. 
 
The mechanisms regulating the monoubiquitination of PCNA by Rad18 are 
poorly understood, and, specifically, it is not known what regulates the redistribution 
of Rad18 to stalled replication forks or how it interacts with its monoubiquitination 
target, PCNA. Rad18 is normally distributed diffusely throughout the nucleus, but it 
redistributes to discrete nuclear foci and colocalizes with PCNA after DNA damage 
(Figure 1-9).101 Rad18 redistribution is intimately coupled with Polη redistribution 
and activity; in addition to its E3 ligase activity, Rad18 physically associates with 
Polη and contributes to its redistribution to PCNA at stalled replication forks (Figure 
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1-9).86 Rad18 thus drives TLS by physically chaperoning Polη to stalled RFs in 
addition to its accepted role of monoubiquitinating PCNA. Indeed, loss of Rad18 
eliminates PCNA monoubiquitination and severely compromises redistribution of 
Polη to replication nuclear foci after UV damage (Figure 1-10), though 
distinguishing between these two functions – E3 ligase activity at PCNA and physical 
chaperoning – has proven technically challenging (see Chapter 2). 
 
Figure 1-9. Rad18 redistributes to nuclear foci after UV exposure and colocalizes with Polη and 
PCNA.  
(images by MD; RFP-PCNA pseudo-colored in blue for clarity). 
 
 
Although Rad18 plays an important role in driving TLS polymerase 
recruitment to sites of DNA damage, the regulatory mechanisms that coordinate this 
process are only beginning to be delineated. As mentioned above, Rad18-Polη 
binding is stimulated by Chk1-dependent Cdc7 phosphorylation of Rad18.80 In 
addition to the kinase-independent role of Chk1 that potentiates PCNA 
monoubiquitination, direct interactions between RPA and Rad18 contribute to Rad18 
redistribution to stalled replication forks.102 Checkpoint signaling therefore regulates 
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Rad18 activity and cellular distribution at several levels, ensuring tight coordination 
between the acquisition of DNA damage and TLS activation. 
 
Figure 1-10. Polη redistribution to nuclear foci after UV exposure is compromised after 
depletion of Rad18.  
(images by MD) 
 
7. XPV and TLS 
Xeroderma pigmentosum (XP) is a rare cancer propensity syndrome defined 
by exquisite sensitivity to sunlight and extremely high predisposition to skin cancer. 
XP affects both males and females equally and follows a pattern of autosomal 
recessive transmission. XP has been reported in nearly all racial groups with 
incidences that vary from 1 in 20, 000 in Japan to 1 in 250, 000 in the USA.103 About 
60% of XP individuals first show symptoms of an extreme sunburn reaction to 
sunlight, often shortly after birth.103 The remaining 40% do not experience dramatic 
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sunburn reactions, but rather develop an unusually high number of freckle-like lesions 
in sun-exposed areas, typically by age 2. 
XP tends to follow a pattern of three stages. While the skin appears healthy at 
birth, the first stage usually begins after about 6 months and is characterized by 
diffuse erythema, scaling, and areas of increased pigmentation in sunlight-exposed 
areas.103 The second stage is characterized by skin atrophy, telangiectasias, and mixed 
hyperpigmentation and hypopigmentation, a combination of symptoms known as 
poikiloderma. The third stage involves the progression to malignancy. XP patients are 
estimated to have a 10,000-fold increased risk of non-melanoma skin cancer and a 
2,000-fold increased risk of melanoma before the age of 20.104 Additionally, ocular 
abnormalities, including photophobia, conjunctivitis, and ocular neoplasms, occur in 
approximately 80% of XP patients, and approximately 20% develop neurologic 
problems, including intellectual deficiency, spasticity or ataxia, and microcephaly. 
The cutaneous symptoms of XP, including pigmented skin lesions sunlight-
exposed skin, were first documented in 1874 in Vienna by a dermatologist named 
Moriz Kaposi,105 and neurologic abnormalities were first described in the 1880’s.106 
However, it wasn’t until the 1960’s that the connection between XP and DNA 
damage tolerance was appreciated when cultured XP cells were shown to exhibit 
deficiency of excision repair.52 In 1971, an excision repair-proficient XP strain was 
described107 and subsequently named “variant.”108 Complementation experiments in 
the 1970’s led to identification of 7 XP subtypes, complementation groups A-G, all 
deficient in nucleotide excision repair, and XP-Variant, which exhibited normal 
excision repair but defective DNA synthesis after UV exposure.109 The genes 
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responsible for each complementation group and their function were subsequently 
identified (Table 1-4). 
Table 1-4. Xerderma Pigmentosum complementation groups and 
their defective gene products. 
Group Defective Gene/Protein Function % of XP
110 
XPA  XPA/XPA Binding to UV-damaged DNA111 25 
XPB ERCC3/XPB DNA helicase112 <1 
XPC  XPC/XPC Binding to UV-damaged DNA 113 25 
XPD ERCC2/XPD DNA helicase114 15 
XPE DDB2/DDB2 Binding to UV-damaged DNA115 <1 
XPF ERCC4/ERCC4 Endonuclease116 6 
XPG ERCC5/XPG Endonuclease117 6 
XPV POLH/Polη TLS 21 
 
XP-Variant (XPV) is unique among the XP complementation groups for 
several reasons. Unlike groups A-G, which are deficient in proteins that mediate 
repair of UV-damaged DNA via NER, XPV is characterized by deficient TLS-
mediated tolerance of UV-induced DNA damage while maintaining normal NER. 
DNA lesions are not actually repaired or removed after TLS, but rather remain in the 
genome until other mechanisms, like NER, remove them. TLS, rather, allows 
replication to continue after a replicative polymerase encounters a DNA lesion, thus 
promoting tolerance of such lesions by preventing replication fork collapse and 
subsequent DNA breaks. The deleterious effects of XPV are thus due to an entirely 
different mechanism of coping with UV-damaged DNA (tolerance vs. repair), in 
addition to a different pathway (TLS vs. NER). 
Next, mutations in XPV individuals arise via different mechanisms than the 
other XP subtypes. Let’s first consider NER. NER can be considered as the first-line 
of defense against DNA damage, through which the vast majority of DNA lesions are 
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removed via relatively error-free processing. As mentioned earlier, the daily burden 
of DNA lesions is enormous, estimated in the range of greater than 10,000 DNA 
lesions per day.16 In a healthy cell, only a very small percentage of these lesions 
escape NER to be processed by other DNA damage tolerance mechanisms. Due to the 
inherent infidelity of TLS enzymes, lesion bypass by TLS will introduce some level 
of mutation, even when each lesion is processed by the appropriate polymerase (e.g. 
CPDs by Polη). In other words, TLS of CPDs by Polη carries a greater risk of 
mutation than normal replication of undamaged DNA by replicative polymerases. 
Such TLS accounts for at least a large part of the basal mutation rate experienced by 
all cells over time, even those with intact DNA damage tolerance pathways. 
However, in the absence of NER, the burden of DNA lesions that must be 
processed by secondary damage tolerance mechanisms is enormous. Again in light of 
the relatively error-prone nature of TLS, lesion bypass via TLS, even when the 
appropriate TLS polymerase is present, will greatly increase the probability of 
introducing mutations. In the absence of NER, one can assume that Polη is still 
performing the vast majority of TLS across UV-induced lesions. Even though Polη-
mediated TLS of CPDs is relatively accurate compared to TLS of CPDs by other TLS 
enzymes, it is still far less accurate than replication of undamaged templates by 
replicative polymerases. Therefore, tolerance of UV-induced DNA damage carries a 
dramatically higher risk of mutagenesis in XP A-G, even though Polη is present to 
perform TLS of CPDs. Indeed, one can assume that the majority of these mutations 
are in fact introduced by Polη itself. 
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The situation in XPV is entirely different and conceptually much simpler. The 
overwhelming majority of UV-induced lesions are removed by NER. Rarely, a CPD 
that escapes NER will be processed by TLS. However, the preferred polymerase for 
CPDs is absent (Polη), so polymerases that are far more error-prone than Polη on 
CPDs (Polι and Polκ) are used instead. Indeed, Polι and Polκ have been implicated in 
mutagenic TLS in the absence of Polη in XPV cells.118 Mutagenesis in XPV is thus 
due to TLS by polymerases other than Polη, whereas Polη plays an important role in 
mutagenesis in XP A-G. 
On a molecular level in XPV cells, the effect of Polη deficiency in the 
response to CPDs that escape NER can be viewed as having two most likely 
outcomes. In the first, CPDs are simply not bypassed and persistent stalling of 
replicative polymerases leads to replication fork collapse and single and double-
strand DNA breaks, with obvious deleterious consequences for genomic stability 
(Figure 1-11, left). Alternatively, TLS may occur via the inappropriate TLS 
polymerase, which will bypass CPDs with a much lower fidelity than Polη and a high 
probability of introducing mutations (Figure 1-11, right). Both potential outcomes 
severely compromise the genetic integrity of the cell and predispose to malignant 
transformation. 
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Figure 1-11. Polη deficiency and processing of UV-induced DNA damage 
Lack of Polη leads to two main outcomes in XPV cells after UV irradiation. Persistent 
stalling of replicative polymerases (left) leads to long stretches of ssDNA that are 
vulnerable to double strand breaks, which can be repaired by non homologous end-
joining, predisposing to DNA translocations. Alternatively recruitment of inappropriate 
TLS polymerases (predominantly Polι and Polκ) predisposes to mutagenic replication 
(right). 
 
 
8. Oncogenic signaling and TLS  
Mutations are well-accepted to play an important role in the initiation and 
progression of many types of cancer.119 Mutations contribute to malignant 
transformation when they inactivate tumor suppressor genes or activate oncogenes; 
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however, the rate of de novo mutations is significantly higher in transformed cells 
compared to normal. Whereas mutation rates in non-transformed cells appear to be in 
the range of 1X10-10 mutations/base pair/cell generation,120,119 mutation rates in 
neoplastic cells have been shown to be over 20-fold higher,121 and gene amplification 
has been shown to be >106-fold higher in tumor compared to normal cell lines.122 
These data suggest that normal processes of genome maintenance are derailed in 
malignant cells, leading to inhibited or mis-regulated damage tolerance mechanisms 
in the context of oncogenic signaling and, in turn, increased mutagenesis. 
Central to this idea is the hypothesis that pre-malignant cells acquire somatic 
mutations that lead to aberrant expression of genes involved in processes important 
for malignancy, namely cell growth, arrest, invasion, replication, and 
angiogenesis.123,124 In particular, aberrant expression and regulation of proteins 
involved in replication and genome maintenance predisposes to additional subsequent 
mutations in a feed-forward cycle carrying a dramatic risk of cancer.125 Because TLS 
is an error-prone replication process, mis-regulation of TLS in oncogene-expressing 
cells would run a high risk of introducing early genetic mutations. 
One can thus hypothesize that oncogene-expressing cells exhibit a reduced 
ability to respond properly to environmental DNA damaging agents (e.g. UV light 
and PAHs) or endogenous replication impediments (G4 structures). Similarly, one 
may hypothesize that TLS alone could be improperly activated or regulated in 
oncogene-expressing cells, leading to excessive error-prone replication. Malignant 
cells would thus acquire mutations at an increased rate due to overactive or mis-
regulated TLS. Evidence has been reported that directly supports this hypothesis,126 
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and the well-accepted role of environmental DNA damaging agents in carcinogenesis 
can be further explained by such mechanisms.127,128 Additionally, oncogene 
expression is known to induce stalling and collapse of DNA replication forks,129 as 
well as replication stress that activates DNA damage responses.130 For example, 
oncogenes have been shown to induce re-replication,131, 132 activate DNA damage 
response pathways,132 and induce the formation of reactive oxygen species (Figure 1-
12).133  
 
 
Figure 1-12. Oncogene-induced DNA replication leads to a DNA damage response that may 
involve TLS. 
 
All of these processes contribute to genetic instability in the context of 
oncogenic signaling; however, the mechanisms through which oncogenes lead to 
genetic instability are poorly understood. Expression of oncogenes leads to several 
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seemingly contradictory cellular responses. Oncogenes such as Ras are known to 
induce cellular proliferation, but only when expressed in combination with the 
inactivation of tumor suppressors, such as p53 or Rb.134 Rather, expression of 
oncogenes leads to an initial wave of proliferation that is followed by cellular 
senescence. Such oncogene-induced senescence is characterized by irreversible 
growth arrest that is associated with accumulation of tumor suppressor genes such as 
p53, p16, or p21.135 Therefore, cells respond to oncogenic signaling by expressing 
proteins that halt cellular proliferation. Importantly, expression of such tumor 
suppressor genes is a consequence of an oncogene-induced DNA damage response.131 
Specifically, oncogene-expressing cells demonstrate DNA replication stress in the 
form of stalled replication forks and DSBs, together with a concomitant activation of 
checkpoint proteins, such as ATM and ATR, and their downstream effectors, Chk2 
and Chk1.136 Importantly, abrogation of these checkpoint responses suppresses 
oncogene-induced senescence.131 Therefore, DNA damage response and checkpoint 
pathways play an integral role in the cellular response to oncogenic signaling; 
however, the mechanisms of oncogene-induced checkpoint activation, the 
consequences of such activation, and the DNA damage response pathways affected 
by such checkpoint activation remains unknown. 
As shown blow (see chapter 4) and in numerous reports,67, 80 there is a clear 
relationship between checkpoint signaling and TLS, and several lines of evidence 
suggest that TLS may be involved in the cellular response to oncogene-induced DNA 
damage. First, because activation of Chk1 stimulates TLS, oncogene-induced 
checkpoint activation is likely to affect TLS via similar mechanisms as other forms of 
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DNA damage. Next, TLS is known to contribute to cellular tolerance of abnormal 
DNA structures, such as G4 DNA, and oncogene-induced replication stress leads to 
aberrant topological DNA structures, such as reversed replication forks;130 TLS may 
also play a role in the processing of such oncogene-induced DNA structures. 
Considering the predilection for mutagenesis in the context of oncogenic signaling 
and the connections between TLS and checkpoint signaling, we have hypothesized 
that TLS is involved in the tolerance of oncogene-induced replication stress and that 
TLS plays an important role in oncogene-dependent mutagenesis (Figure 1-12). 
Important unexplored questions include whether TLS is activated in the 
context of oncogenic signaling, whether checkpoint activation impacts oncogene-
dependent TLS activity, how TLS contributes to mutagenesis in the context of 
oncogene expression, and whether oncogene-expressing cells are sensitized in the 
absence of TLS-mediated DNA damage tolerance. 
 
 
9.  Remaining major unkowns  
The preceding text is intended to provide a background of specific areas 
relevant to the studies presented in this dissertation. For each area, however, several 
important processes have remained unknown: 
DNA Damage Response Checkpoints and TLS 
Although it is clear that checkpoints facilitate activation of TLS via signaling 
mechanisms (Chk1-dependent binding of Rad18 and Polη) and direct physical 
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interactions (kinase-independent Chk1-mediated potentiation of PCNA 
monoubiuqitination), a broader understanding of the relationship between checkpoint 
signaling and TLS is needed. Specifically, it remains entirely unknown whether 
checkpoint signaling contributes to binding of other TLS polymerases with Rad18, 
the mechanism through which Chk1 facilitates recovery from genotoxin-induced S-
phase checkpoints, and what additional effector proteins function upstream and 
downstream of Chk1 to initiate a TLS-stimulatory checkpoint response. 
Understanding these concepts will help explain the mechanisms through which TLS-
mediated damage tolerance and mutagenesis take place. These concepts are addressed 
in Chapter 4 of this dissertation. 
Rad18 and TLS Activation 
 Although Rad18/Rad6 is known to catalyze damage-responsive 
monoubiquitination of PCNA, the mechanisms that regulate this process remain 
entirely unknown. It is known that Rad18 does not physically interact with PCNA, so 
the processes that drive redistribution of Rad18 to PCNA and subsequent physical 
binding of the two are unknown. Additionally, whereas UV-induced binding of 
Rad18 and Polη has been clearly demonstrated, the specific mechanistic aspects of 
this interaction remain unknown: where does Polη bind to Rad18 and vice versa? Do 
known effector domains of Polη, such as the UBZ domains, contribute to Rad18 
binding? Where does this interaction take place? Is the interaction direct or are other 
binding partners required? Do the components of the Rad18-Polη complex change as 
a function of genotoxin stimulation or cell cycle? Further, details of analogous Rad18 
interactions with TLS polymerases remain unknown. What are the binding domains 
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necessary for Rad18-Polκ interactions? Are these interactions promoted only by 
BPDE? Does Rad18 interact at all with Polι or Rev1? Finally, the mechanisms that 
dictate selection of the proper polymerase for the appropriate DNA lesion are 
completely unknown. This point is of crucial importance because use of the wrong 
polymerase greatly predisposes to mutagenesis. Additionally, because of the role that 
TLS plays in cellular tolerance anticancer drugs such as cisplatin,137 understanding 
the mechanisms that regulate TLS initiation and activation may help guide the 
development of therapeutic targets. 
Oncogenes and TLS 
 It is widely accepted that oncogenic signaling activates a DNA damage 
response and checkpoints and simultaneously promotes mutagenesis in a manner that 
feeds into the mutator phenotype. However, it remains entirely unknown what are the 
consequences of such oncogene-induced activation of the DDR and what mechanisms 
are responsible for the oncogene-induced increase in mutagenesis. A putative role for 
TLS in this process is conceptually feasible but has never been explored. A role for 
TLS in the tolerance of oncogenic replication stress concepts is addressed in Chapter 
5. Understanding the mechanisms that dictate mutagenesis and survival in the context 
of oncogenic signaling is necessary for the discovery of novel targets for anti-
proliferative therapies. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
1. Cell Culture and Transfection 
H1299, HDF, XP115LO (GM0235946, 138), and HCT-116 WT and Rad18-/- cells139 
cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) and penicillin–streptomycin. SiRNA and pcDNA, 
pACCMV, and pCAGGS plasmid transfections were done using Lipofectamine 2000 
(Invitrogen) as previously described80. 
 
2. Materials, siRNA, plasmad and adenovirus construction 
siRNA oligonucleotide sequences were as follows: non-targeting Control, 5′–
UAGCGACUAAACACAUCAAUU–3′; Polη, 5′–GCAGAAAGGCAGAAAGUUA–
3′; Polη-3′ UTR, 5′–CCAUUUAGGUGCUGAGUUA–3′; Polη-5′ UTR, 5′–
GAAUAAAUCUCGCUCGAAA–3′; Chk1, 5′–GCGUGCCGUAGACUGUCCA–3′; 
USP1, 5′–TCGGCAATACTTGCTATCTTA–3′; Polκ, 5′–
GUAAAGAGGUUAAGGAAA–3′; Rad18 3′ UTR, 5′–
UUAUAAAUGCCCAAGGAAAUU–3′; Spartan 5′–
ACCGGACUUGCAGGCACUGUUUGUU–3′. CFP was cloned onto the C-terminus 
of Rad18 in pACCMV using BamH1 and Xba1 restriction sites. Rad18 and CFP were 
separated by a linker of the sequence 5′–
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ACCTCTTCCGGTTCCAGTCCCTGTTCCGGGTCCTGCTCCTATGCGTATGGC
TCC–5′. Rad18-Δ(402-225) and Rad18-C28F were generated as described 
previously86 and cloned into pACCMV using EcoRI and BamHI restriction sites. 
Polη-ΔPIP was cloned into pACCMV EcoRI and BamHI restriction sites and a C-
terminal primer containing phenylalanine to alanine mutations at AA 705 and 707. 
Catalytically-inactive Polη was generated by mutating codons D13, E22, D115, and 
E116 to alanine in the N-terminal catalytic active site to disrupt coordination of Mg2+ 
ions between dNTP, primer, and active site moieties and block nucleotide 
incorporation140; this construct was then cloned into pACCMV using EcoRI and 
BamHI restriction sites. N-terminal Polη truncations were generated with 5′ and 3′ 
primers containing EcoRI and BamHI restriction sites, respectively, and cloned into 
pACCMV. The Rad18-Polη fusion was constructed by PCR amplification of Polη 
with primers containing 3′ BamHI and 5′ XbaI restriction sites, followed by ligation 
into pACCMV-Rad18. Polη-ΔPLTH and Polκ+PLTH were generated with C-
terminal primers omitting or adding, respectively, codons for the PLTH domain, 
followed by a BamHI restriction site for ligation into pACCMV. pDEST-SFB-
Spartan was obtained from Lee Zou (MGH Cancer Center). Adenovirus constructions 
were performed by recombination of pACCMV constructs with pJM17 as described 
previously141. UV-C irradiation using a UV cross-linker (Stratagene, Santa Clara, 
CA) and BPDE (NCI Carcinogen Repository) treatments were performed as 
previously described.142 
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3. Adenovirual expression and titration 
Adenoviral infection was performed as described previously by adding to cultured 
cells CsCl purified adenovirus.141 Infections in H1299 cells were typically done at 0.1 
− 1.0×109 pfu/mL and in XPV/HDF cells at 0.1 − 5.0×109 pfu/mL. Titration to 
expression levels approximately equal to endogenous was done by serial infections 
followed by immunoblotting of extracts with antibodies against the endogenous 
protein. 
 
4. Fluorescence microscopy 
H1299 or XPV cells were grown to ~ 60% confluency on glass-bottom plates (Mat-
tek) and then infected with adenovirus (CFP-Rad18-WT, YFP-Polη, GFP-Polκ, and 
respective mutants) to achieve expression approximately equal to endogenous as 
determined by Western blot. For co-expression and knockdown experiments, co-
infection or transfection were performed 6 hours before adenoviral infection. 20 hours 
after infection, cells were exposed to genotoxins and then prepared for live or fixed-
cell imaging on a Zeiss 710 confocal microscope. For high-magnification 
representative images, Z-stacks at 0.5 um intervals were collected throughout the 
entire cell volume using a 63X oil-immersion objective and 2.3X optical zoom. 3D 
projections of Z-stacks were performed using Grouped Zprojector on ImageJ. For 
cells expressing multiple chromophores (YFP and CFP-tagged proteins) appropriate 
excitation lasers, laser intensities, and emission filter bandwidths were selected to 
eliminate bleedthrough. For live-cell imaging, cells were kept out of the incubator for 
no more than 10 minutes. For fixed-cell imaging, H1299 cells were washed 3X with 
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cold PBS, then extracted for 60 s in cold CSK buffer, washed 3X with PBS, then 
fixed for 10 min in 2% PFA in PBS; XPV cells were washed 3X in cold PBS and then 
fixed for 15 min in methanol at -20C. Post-fixation, all cells were covered with 
Vectashield Solution (Vector Laboratories) and imaged within 24 hours. For foci 
quantification, five representative images containing approximately 60 cells were 
captured using 0.5 um Z-stacks with a 40X using oil-immersion lens. After 3D-
projection, and the number of cells clearly containing more than 100 nuclear foci 
were counted as a fraction of total chromophore-expressing cells. 
 
5. Triton extraction, immunoprecipitation, and immunoblotting 
Extracts containing soluble and chromatin-associated proteins were prepared as 
previously described80 by lysing cultured cells into cold cytoskeleton buffer (CSK 
buffer; 10 mM Pipes, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM 
EGTA, 1 mM DTT, 0.1 mM ATP, 1 mM Na3VO4, 10 mM NaF, and 0.1% Triton X-
100) supplemented phosphatase and protease inhibitors (Roche Diagnostics, 
Indianapolis, IN). For immunoprecipitation of whole cell lysate (WCL) or chromatin-
bound proteins, Triton-insoluble proteins were released by sonication on ice for three 
10 s intervals followed by centrifugation at 15k x g for 10 min. After normalizing to a 
protein concentration of 1 ug/ul, immunoprecipitation was conducted at 4°C by 
rotating overnight with HA-coupled or primary antibody-bound sepharose beads 
(Roche Diagnostics, Indianapolis, IN). After immunoprecipitation, the beads were 
washed five times for 15 min in CSK buffer and then resuspended in minimum 
volume of Laemmli buffer. For Immunoblot experiments, cell extracts or 
  
 
40 
immunoprecipitates were separated by SDS-PAGE, followed by incubation overnight 
with the following primary antibodies: PCNA (sc-56), Chk1 (sc-7898), β-Actin (sc-
130656), all from Santa Cruz Biotech (Santa Cruz, CA); Polη (A301-231A), Polκ 
(A301-975A), Polι (A301-304A), and R18 (A301-340A), all from Bethyl 
Laboratories (Montgomery, TX); and p53 (Ab-6) from Lab Vision, (Fremont, CA). 
 
6. Genotoxin treatments 
UV-irradiation and BPDE treatment were performed as previously described 80, and 
BPDE (National Cancer Institute Carcinogen Repository) was dissolved in anhydrous 
Me2SO and added directly to the growth medium as a 1000× stock to give various 
final concentrations, as indicated in the figure legends. For UVC treatment, the 
growth medium was removed from the cells, reserved, and replaced with phosphate-
buffered saline (PBS). The plates were transferred to a UV cross-linker (Stratagene, 
Santa Clara, CA) and then irradiated. The UVC dose delivered to the cells was 
confirmed with a UV radiometer (UVP BioImaging Systems, Upland, CA). The 
reserved medium from the cells was replaced, and cells were returned to the 
incubator. 
 
7. In vitro Binding and Ubiquitination assays 
C-His6-PCNA-expressing Top10 E. coli (acquired from Marila Cordiero-Stone, 
UNC-CH) were collected and lysed in pH 8 buffer containing 50 mM NaPO4, 300 
mM NaCl, 20 mM imidazole, and 0.1% Triton-X. After sonication and clarification, 
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His6-PCNA was purified over Ni-NTA beads. For His6-PCNA pulldown experiments, 
HA-Rad18 was adenovirally expressed in H1299 cells alone or together with YFP-
Polη and lysed in NaPO4/NaCl/imidazole/Triton-X buffer. After sonication, 
clarification, and normalization to a protein concentration of 1 ug/ul, cell lysates were 
rotated overnight at 4°C with His6-PCNA on Ni-NTA beads. The beads were then 
washed 5 times in the same buffer before addition of Laemmli buffer, boiling, and 
analysis by SDS-PAGE/Western Blot. For in vitro ubiquitination assays, H1299 cells 
expressing HA-Rad18 alone or together with YFP-Polη were lysed in 
NaPO4/NaCl/imidazole/Triton-X buffer and immunoprecipitated with HA-sepharose 
beads. After washing the beads extensively, the beads were resuspended in 50 uL 
buffer and the following were added: His6-PCNA (eluted from Ni-NTA beads with 
the same buffer plus 200 mM imidazole), 500 uM FLAG-ubiquitin, 10 X Energy 
Regeneration Solution, and 100 nM Ubiquitin Activating Enzyme (UBE1), all from 
Boston Biochem (Cambridge, MA). After incubation for 16 hours at 4°C, the mixture 
was mixed with Laemmli buffer, boiled, and analyzed by SDS-PAGE and Western 
Blot. 
 
8. UV cytotoxicity assays 
XPV or HDF cells were split into 24-well plates to a density of approximately 25%. 
12 hours later, the cells were infected with empty control adenovirus or adenovirus 
expressing YFP-Polη. 24 hours after infection, the cells were exposed to UV light in 
the presence or absence of 1 mM caffeine. After 48 hours, 50 mg/ml Thiazolyl Blue 
Tetrazolium Bromide (MTT) (Sigma-Aldrich, St. Louis, MO) was added to each well 
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and let to incubate at 37°C for 2 hours. The cells were then rinsed with PBS and 
dissolved in 0.5 mL DMSO. The absorbance at 570 nm was then measured for each 
well and normalized to the sham-treated samples. The minimum dose of YFP-Polη 
that conferred resistance to UV light in XPV cells (approximately 0.5×109 pfu/mL, 
Figure 2-1) was determined by this method and used for survival assays. 
 
 
Figure 2-1. Killing curves for XPV cells complemented with Polη. 
UV-sensitivity of XP115LO cells infected with adenovirus expressing YFP-Polη and exposed 
to increased doses of UV 24 hours later in the absence (left) and presence of 1mM caffeine 
(right). Caffeine was added to cells 2 hrs before UV and maintained for duration of the 
experiment. Cell viability was assayed by MTT 48 hrs after UV. The minimum dose of YFP-
Polη virus (approximately 4x108 pfu/mL, blue circles) that yielded 100% UV survival at 12 
J/m2 UV was used for all ectopic expression experiments in XP115LO and HDF cells. 
 
 
9. In vitro kinase assays 
Recombinant Rad18–Rad6 complex from insect cells and GST-Rad18 from bacteria 
were expressed, purified, and tested as DDK and JNK substrates using in vitro 
phosphorylation reactions as described previously.80 Recombinant DDK was purified 
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from insect cells as described previously,80 and recombinant JNK1α1 was purchased 
from Upstate (Millipore, Billerica, MA). 
 
10. Clonogenic survival assays 
H1299 cells were grown to ~30–50% confluence in 60-mm plates and transfected 
with 4 µg of pAC.CMV GFP vector (for controls) or with pAC.CMV expression 
vectors encoding wild-type or mutant Rad18 using Lipofectamine. Transfected cells 
were treated with UVC (as described) and then split into replicate 10-cm plates at a 
density of 1000 cells/plate. After 10–14 d, colonies on the plates were fixed in 
methanol, stained with crystal violet, and counted as described previously.80 
 
11. Statistics 
P values for statistical significance were determined by the unpaired Student’s t-test 
with a two-tailed 95% confidence interval. 
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CHAPTER 3 
 
A NOVEL NON-CATALYTIC FUNCTION OF DNA POLYMERASE η IN 
PROMOTING PCNA MONOUBIQUITINATION AT STALLED REPLICATION 
FORKS1 
 
1. Introduction 
Living organisms are constantly exposed to ubiquitous genotoxins from 
endogenous and external sources.143 However, cells have evolved numerous DNA 
damage response (DDR) pathways that protect genomic DNA and prevent genetic 
instability.144 Translesion Synthesis (TLS) is a DDR mechanism involving specialized 
DNA polymerases that can replicate damaged DNA templates. 145 
TLS relies on inherently error-prone DNA Polymerases of the Y family to 
replicate damaged DNA.146 TLS by Y-family polymerases (Polη, Polι, Polκ, and 
Rev1)147 maintains replication in cells harboring damaged DNA, albeit at the cost of 
reduced fidelity. Each TLS polymerase performs relatively error-free replication past 
a preferred cognate lesion; in the absence of the appropriate TLS polymerase for its 
preferred lesion, mutagenic replication by error-prone polymerases predisposes to 
genetic instability.144 
Polη is unique among Y-Family Polymerases in its ability to perform accurate 
replication past UV-damaged DNA.109, 148 Lack of Polη in the inherited cancer-
                                                
1 This chapter is based on the following manuscript, which was accepted for publication in December 
2012: Durando M, Tateishi S, Vaziri C. A non-catalytic role of DNA polymerase η in recruiting Rad18 
and promoting PCNA monoubiquitination at stalled replication forks. Nucleic Acids Res. 2013 Mar 
1;41(5):3079-93. 
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propensity syndrome xeroderma pigmentosum Variant (XPV)149 results in error-prone 
replication by other Y-family Polymerases in sunlight-exposed cells.118, 150 Thus, UV-
induced mutagenesis due to Polη-deficiency compromises genetic integrity to 
manifest as exquisite sunlight-sensitivity and early skin cancer-propensity. 
A prerequisite for error-prone replication in TLS is the Rad6/Rad18-mediated 
monoubiquitination of PCNA at the highly conserved lysine K164.93, 151 Y-family 
polymerases contain ubiquitin-binding (UBZ) domains that confer affinity to 
monoubiquitinated PCNA.94, 152 Failure to monoubiquitinate PCNA at K164 
phenocopies XPV by compromising TLS and sensitizing cells to UV light and other 
ubiquitous genotoxins.98, 153-155 Several other DDR pathways also depend on PCNA 
monoubiquitination, including SHPRH/HTLF-mediated template switching,156 
ZRANB3-dependent replication fork restart,157 SNM1A-dependent intrastrand cross-
link repair,158 the Fanconi Anemia pathway activation.159 
In spite of its pivotal role in the DDR, the molecular mechanisms regulating 
Rad18-mediated PCNA monoubiquitination are incompletely understood. The 
Rad18-Rad6 complex is thought to be recruited to the vicinity of damaged DNA via 
direct interactions with RPA-coated ssDNA.102, 160 However, Rad18 lacks PCNA-
binding motifs and it is unclear how Rad18 is targeted specifically to PCNA at stalled 
forks (or other sites of post-replication repair). A recent report by Zou and colleagues 
identified Spartan as a binding partner of both Rad18 and PCNA and proposed that 
Spartan acts as a scaffold for recruiting Rad18 to PCNA.161 Consistent with a role for 
Spartan in targeting Rad18 to PCNA, those workers found DNA damage-induced 
PCNA monoubiquitination was modestly attenuated in Spartan-depleted cells. 
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However, several other more recent publications have reported alternative roles for 
Spartan in DNA damage signaling162-165 and it is unclear whether Spartan or 
alternative putative mediators exist to facilitate recruitment of Rad18 to PCNA. 
In mammalian cells, Rad18 exists in complex with Polη 80, 86 and association 
of Rad18 with Polη is necessary for normal DNA damage tolerance.80, 86, 142 
Assembly of the Rad18-Polη complex is stringently controlled by Cdc7 and Chk1 
kinases, which serve to integrate TLS with S-phase progression and the S-phase 
checkpoint respectively.80, 142 Here we report that the Polη-Rad18 interaction plays a 
key role in targeting Rad18 to PCNA and facilitating efficient PCNA 
monoubiquitination. Interestingly, the novel role of Polη in stimulation of PCNA 
monoubiquitination is fully dissociable from its activity as a DNA polymerase. We 
show that the Polη-Rad18 interaction provides the basis for coupling PCNA 
monoubiquitination with DNA damage-inducible checkpoint pathways mediated by 
p53 and Chk1. Our results also provide a potential explanation for numerous reports 
that Polη confers tolerance of non-cognate lesions166, 167 and that catalytically-inactive 
Polη can partially rescue the DNA damage-sensitivity phenotypes of XPV cells.168, 169 
Moreover, because some XPV cells express a catalytically-inactive Polη that retains 
the ability to promote PCNA monoubiquitination, our results also indicate a new 
molecular mechanism for the mutagenesis and cancer-propensity of XPV patients.  
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2. Results 
2.1. Polη promotes Rad18-mediated PCNA 
monoubiquitination  
Current models suggest that Rad18 plays proximal roles in TLS, chaperoning 
Polη to damaged chromatin and monoubiquitinating PCNA to stably engage Y family 
polymerases at sites of PRR.93, 94 Unexpectedly, we observed deficient redistribution 
of Rad18 to nuclear foci (representing sites of replication stalling) in patient-derived 
XPV cells (XP115LO) following UV-irradiation (Figure 3-1 A, B). In Polη-corrected 
XP115LO cells, Rad18 redistributed to nuclear foci in a UV-inducible manner and 
co-localized with Polη, indicating that Rad18 redistribution to repair foci is Polη-
dependent in XP115LO cells. Similar to results obtained with XPV cells, 
redistribution of Rad18 was defective in Polη-depleted H1299 cells (Figure 3-1 C, 
E), which have intact TLS and rely on Polη for UV-tolerance.80 As shown in Figure 
3-1 D, basal and UV-induced formation of Rad18 foci were dependent on Polη, 
indicating a general role for Polη in impacting Rad18 redistribution. 
We next asked whether Polη status also affected PCNA-directed Rad18 E3 
ligase activity. Polη-complemented XPV cells exhibited higher basal and damage-
induced PCNA monoubiquitination compared to parental XPV cells, and Polη 
expression was associated with increased chromatin-binding of Rad18 (Figure 3-1 
F). Conversely, UV-induced PCNA monoubiquitination was compromised in Polη-
depleted normal Human Diploid Fibroblasts (HDF) relative to Polη-replete controls 
(Figure 3-1 G). Polη depletion thus partially phenocopies the expected effect of 
depleting RPA, which is thought to initiate TLS by coating ssDNA and triggering 
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ATR/Chk1 signaling and subsequent PCNA monoubiquitination.66, 67 Rad18 
redistribution and PCNA monoubiquitination were also attenuated in Polη-depleted 
cells after BPDE-treatment (Figure 3-1 H), indicating that the effect of Polη on 
Rad18 activity is not genotoxin-specific.  
Next, we determined whether increased Polη expression affects Rad18 and 
PCNA monoubiquitination.  When expressed in HCT-116 cells at levels ranging from 
approximately two- to 25-fold higher than endogenous, PCNA monoubiquitination 
increased in a dose-dependent fashion with Polη (Figure 3-1 I). Importantly, PCNA 
monoubiquitination was not induced by Polη in isogenic Rad18-null HCT-116 cells, 
indicating that the effect of Polη on PCNA modification is Rad18-mediated (Figure 
3-1 I, right lane). 
Potentially, the stimulatory effect of Polη expression on PCNA 
monoubiquitination could result (at least in part) from reduced PCNA de-
ubiquitylation activity. Ubiquitin-Specific Protease 1 (USP1) is the only known 
PCNA-directed de-ubiquitylating (DUB) enzyme.170 To determine whether inhibition 
of USP1 activity contributes to Polη-dependent PCNA monoubiquitination, we 
determined the effects of Polη-expression on PCNA modification in USP1-depleted 
cells. As expected, basal levels of PCNA monoubiquitination were increased by 
USP1-depletion (Figure 3-1 J). However, Polη expression further increased PCNA 
monoubiquitination in cells lacking USP1 (compare lanes 2 and 8), both basally and 2 
and 8 hours after DNA damage. We conclude that that Polη stimulates PCNA 
monoubiquitination by Rad18 via USP1-independent mechanisms. We cannot 
exclude the formal possibility that Polη-dependent PCNA monoubiquitination is not 
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mediated by reduced activity of putative alternative PCNA-directed DUBs. However, 
the results of Figure 1 and data presented below indicate that Polη facilitates 
redistribution of Rad18 to sites of DNA damage and promotes efficient PCNA mono-
ubiquitination. 
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Figure 3-1. Polη promotes damage-induced Rad18 redistribution and PCNA 
monoubiquitination.. 
(A) Representative images of CSK-extracted nuclei (top) or live (bottom) from CFP-Rad18-
expressing XP115LO XPV cells co-infected with empty control adenovirus or adenovirus 
expressing YFP-Polη (at levels that restore UV-tolerance - see Supplementary Fig. S1) and 
exposed to UV (10 J/m2) or sham-irradiated.  Scalebar = 10 µm. 
(B) Quantification of CFP-Rad18 foci-positive H1299 nuclei as a percentage of CFP-Rad18-
expressing cells as shown in (A); *, p=0.0001; **, p=0.001. Error bars = SEM. 
(C) Representative images of live (top) and CSK-extracted (bottom) nuclei from H1299 cells 
treated with non-targeting control siRNA (left) or siRNA targeting Polη (right) and imaged 2 
hours after sham or UV (10 J/m2)-irradiation. Scalebar = 10 microns. 
(D) Quantification of CFP-Rad18 foci-positive nuclei as a percentage of CFP-Rad18-
expressing cells as shown in (D). *, p=0.001; **, p=0.0003. 
(E) Immunoblot of fractionated lysates from H1299 cells expressing CFP-tagged Rad18 as 
shown in (D) and treated with non-targeting control siRNA or siRNA against Polη and then 
lysed 2 hours after treatment with 10 J/m2 UV or sham-treated. 
(F) Immunoblot of fractionated lysates from XP115LO XPV cells treated with empty control 
adenovirus or adenovirus expressing YFP-Polη at levels shown in (A) and lysed 2 hours after 
treatment with 10 J/m2 UV. 
(G) Immunoblot of fractionated lysates from HDF cells treated with non-targeting control 
siRNA or siRNA against Polη and then lysed 2 hours after treatment with 10 J/m2 UV or sham-
irradiation. 
(H) Immunoblot of fractionated lysates from HDF cells treated with non-targeting control 
siRNA or siRNA against Polη and then lysed 2 hours after treatment with increasing doses of 
BPDE. 
(I) Immunoblot of fractionated lysates from HCT-116 WT cells (lanes 1-4) or RAD18-/- cells 
(lane 5) treated with increasing titers of YFP-Polη adenovirus and lysed 24 hours post-
infection. Upper and lower arrows denote YFP-tagged and endogenous Polη, respectively.  
(J) Immunoblot of fractionated lysates from H1299 cells expressing empty control adenovirus 
or adenovirus expressing YFP-Polη and treated with non-targeting control siRNA or siRNA 
against USP1 and then lysed at indicated times after treatment with 200 nM BPDE. On all 
Western Blots, asterisk denotes monoubiquitinated PCNA and bar graphs represent intensity of 
monoubiquitinated PCNA band relative to the maximum band on each film. 
 
 
 
2.2. Rad18-Polη interactions drive PCNA 
monoubiquitination  
Because Rad18 and Polη form a complex after DNA damage,86 we next asked 
whether Polη-dependent redistribution of Rad18 and PCNA monoubiquitination 
required Rad18-Polη interactions. The Polη-binding region of Rad18 has been 
mapped to amino acid (AA) residues 402-445 (Figure 3-2 A).86 Therefore, we 
  
 
52 
determined the effect of Polη status on the activity of a Polη-interaction defective 
Rad18 mutant, Rad18-Δ(402-445), that retains E3 Ub-ligase activity and other DNA 
repair functions.86 
Consistent with in vitro binding studies,86 Rad18-Δ(402-445) failed to co-
immunoprecipitate Polη from cell lysates (Figure 3-2 B). To test how Polη-Rad18 
binding affected subcellular Rad18 distribution, we depleted H1299 cultures of 
endogenous Rad18 and reconstituted with near-physiological levels of siRNA-
resistant CFP-Rad18-WT or CFP-Rad18-Δ(402-445). As shown in Figure 3-2 C and 
Figure 3-3, co-expression of Polη significantly increased basal and damage-induced 
redistribution of Rad18-WT to nuclear foci but had no effect on the redistribution of 
Rad18-Δ(402-445). In replicate cultures of Rad18-complemented cells, Polη-induced 
PCNA monoubiquitination was severely compromised in cells complemented with 
Rad18-Δ(402-445) when compared with cells expressing Rad18-WT (Figure 3-2 D, 
compare lanes 1 & 8 to 11 & 12). Therefore, Polη-Rad18 interactions are necessary 
for Polη-dependent PCNA monoubiquitination. 
The stable engagement of TLS polymerases with stalled replication forks 
depends on their UBZ/UBM-mediated interactions with monoubiquitinated PCNA.93, 
94, 152 As expected, the reduced PCNA monoubiquitination in cells complemented 
with Rad18-Δ(402-445) was associated with decreased Polη chromatin binding 
(Figure 3-2 D) and reduced formation of Polη nuclear foci (Figure 3-2 E, F), when 
compared with Rad18-WT-expressing cells. Thus, Rad18-Δ(402-445) partially 
recapitulates phenotypes conferred by the E3 ubiquitin ligase-deficient Rad18-C28F 
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mutant (Figure 3-2 A), including defective PCNA monoubiquitination (Figure 3-2 
G) and reduced recruitment of Polη to chromatin (Figure 3-2 E, F). 
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Figure 3-2. Physical interaction between Rad18 and Polη drives efficient damage-induced PCNA 
ubiquitination. 
(A) Schematic of Rad18-WT (top); Rad18-Δ(402-445), a Polη-binding deficient mutant 
lacking the Polη binding domain (AA 402-445); Rad18-C28F, an E3 ligase-inactive mutant  in 
which the RING-finger cysteine has been substituted with phenylalanine. 
(B) Immunoblot analysis of anti-HA immunoprecipitates from H1299 cells co-expressing HA-
Rad18-WT or HA-Rad18-Δ(402-445) with Myc-Polη. (C) Quantification of CFP-Rad18 foci-
positive nuclei as a percentage of H1299 cells expressing CFP-Rad18-WT or CFP-Rad18-
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Δ(402-445) and treated with empty adenovirus or Myc-Polη-expressing adenovirus followed 
by UV (10 J/m2) treatment or sham irradiation. *, p=0.095; **, p=0.0006. Error bars = SEM. 
(D) Immunoblots of fractionated lysates from Rad18-depleted H1299 cells that were 
reconstituted with siRNA-resistant Rad18-WT, Rad18-Δ(402-445), or empty vector (for 
control) alone or together with FLAG-Polη, followed by treatment with UV (10 J/m2) or sham-
irradiation. 
(E) Representative images of CSK-extracted nuclei from YPF-Polη expressing H1299 cells 
that were depleted of endogenous Rad18 and then reconstituted with siRNA-resistant Rad18-
WT, or Rad18-Δ(402-445), or Rad18-C28F and treated with UV (10 J/m2) or sham-irradiated.  
Scalebar = 10 um. 
(F) Quantification of YFP-Polη foci-positive nuclei as a percentage of YFP-Polη-expressing 
cells in cultures complemented with Rad18-WT, Rad18-Δ(402-445), or Rad18-C28F as shown 
in (E). *, upper p=0.026, lower p=0.0238. 
(G) Immunoblots of fractionated lysates from Rad18-depleted H1299 cells that were 
reconstituted with siRNA-resistant WT-Rad18, C28F-Rad18, or empty vector, and then treated 
with UV (10 J/ m2) or sham-irradiated. 
 
 
 
 
Figure 3-3. Polη overexpression drives Rad18 redistribution to nuclear foci. 
Representative images of live CFP-Rad18-expressing H1299 cells co-infected with empty 
control adenovirus (left) or adenovirus expressing YFP-Polη (right) and treated with UV 
(10J/m2) or sham irradiated. Scalebar = 10 µm. 
 
 
2.3. Polη-PCNA binding drives PCNA monoubiquitination 
C-terminal Polη truncations are the most common defect in XPV,149, 171, 172 in 
which both the PCNA-Interacting Peptide (PIP) box173 and the Rad18-binding 
domains86 are deleted. To test whether Polη XPV C-terminal truncation mutants 
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exhibit defects in Rad18 regulation, we complemented XPV cells with WT-Polη or 
similar levels of a common XPV Polη mutant that retains full catalytic activity174 but 
fails to confer UV-resistance (Polη-Δ(1-512), lacking residues 513-713, Figure 3-4 
A). As expected, complementation of XPV cells with Polη-WT conferred normal 
Rad18 redistribution (Figure 3-4 B, C) and resulted in increased PCNA 
monoubiquitination (Figure 3-4 D). However, complementation of XPV cells with 
Polη-Δ(1-512) failed to restore Rad18 redistribution or PCNA monoubiquitination to 
the same extent as those complemented with Polη-WT (Figure 3-4 B, D), indicating 
that the C-terminal domain of Polη is important not only for Polη chromatin binding, 
but also for Rad18 nuclear redistribution and Rad18-mediated PCNA 
monoubiquitination. 
To test whether loss of PCNA binding contributes to defective PCNA 
monoubiquitination in Polη-Δ(1-512)-complemented XPV cells, we generated point 
mutations in the PIP-box that abrogate PCNA binding 173 (Figure 3-4 A). In Rad18-
depleted cells complemented with physiological levels of Rad18-WT, Polη-WT but 
not Polη-ΔPIP promoted PCNA monoubiquitination by Rad18 (Figure 3-4 E, 
compare lanes 7 & 8 with 11 & 12). Therefore, Polη-PCNA association via the PIP-
box of Polη contributes to maximal Rad18-mediated PCNA monoubiquitination. 
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Figure 3-4. Polη physically bridges Rad18 and PCNA to promote efficient PCNA 
monoubiquitination after DNA damage. 
 (A) Schematic of Polη-WT (top); Polh-Δ(1-512), a C-terminal truncation lacking AA 513-713 
(middle); and Polη-ΔPIP, full length Polη with two PIP-box phenylalanines mutated to alanine 
(bottom). 
(B) Representative images of CSK-extracted nuclei from XPV cells that were co-infected with 
CFP-Rad18 and YFP-Polη-Δ(1-512) adenovirus (left) or YFP-Polη-WT (right) and treated 
with UV (10 J/m2) or sham-irradiated. Scalebar = 10 um. 
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(C) Quantification of CFP-Rad18 foci-positive nuclei as a percentage of CFP-Rad18-
expressing XPV cells expressing YFP-Polη-Δ(1-512) or YFP- Polη-WT adenovirus. *, upper 
p=0.018; **, p=0.0001; Error bars = SEM. 
(D) Immunoblots of fractionated lysates from XPV cells complemented with Polη-WT or 
Polη-Δ(1-512) and treated with 10 J/m2 UV. 
(E) Immunoblots of fractionated lysates from Rad18-depleted H1299 cells that were 
reconstituted with siRNA-resistant Rad18-WT together with FLAG-tagged Polη-WT or Polη-
ΔPIP and treated with sham or 10 J/m2 UV. 
(F) In vitro pulldown assay. His6-PCNA-loaded Nickel beads (or unloaded beads) were 
incubated with lysates from UV-irradiated H1299 cells expressing HA-Rad18 or both HA-
Rad18 and YFP-Polη. 
(G) In vitro ubiquitination assay. HA-Rad18 complexes immunoprecipitated from UV-
irradiated H1299 cells expressing HA-Rad18 alone or in combination with YFP-Polη were 
mixed with recombinant His6-PCNA, E1, FLAG-ubiquitin, and an ATP-regenerating system 
and conjugated FLAG-Ub was detected by immunoblotting with anti-FLAG antibodies. 
 
 
2.4. Polη scaffolding mediates Rad18-PCNA association 
While Polη possesses a PIP-box173, 175 and interacts directly with PCNA,173 no 
PCNA-interacting domain has been identified for Rad18, and the mechanism for 
association of Rad18 with PCNA is unknown. The Polη-dependence of Rad18-
mediated PCNA monoubiquitination (Figures 3-1 - 3-3) suggested that Polη may 
serve as a ‘molecular bridge’ or scaffold to facilitate Rad18-PCNA interactions. To 
test this hypothesis, we developed a cell-free system to determine the Polη-
dependence of PCNA-Rad18 interactions (if any). Recombinant PCNA was 
immobilized on Ni-NTA beads (or unloaded beads for controls) and incubated with 
extracts from cells expressing Rad18 alone or in combination with Polη. When 
extracts from Rad18-expressing cells were incubated with PCNA-Ni beads, we were 
unable to detect association between Rad18 and PCNA (Figure 3-4 F, lane 1). 
However, we readily detected Rad18 association with immobilized PCNA incubated 
with lysates from Rad18 and Polη co-expressing cultures (Figure 3-4 F, lane 2). 
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Therefore, we conclude that Polη promotes Rad18-PCNA interactions or stabilizes 
Rad18-PCNA complexes. 
We modified this cell-free assay to test whether the presence of Polη 
influenced PCNA monoubiquitination by Rad18. HA-Rad18 was expressed in UV-
irradiated H1299 cells individually or in combination with Polη and then 
immunoprecipitated using anti-HA antibodies. The resulting immune complexes were 
then mixed with recombinant PCNA, E1, FLAG-ubiquitin and an ATP-regenerating 
system. As shown in Figure 3-4 G, Rad18 immune complexes conjugated FLAG-
ubiquitin to PCNA in a manner that was stimulated by Polη (compare lanes 2 and 3). 
Taken together, the results of Figure 2-3 suggest that Polη promotes efficient 
PCNA monoubiquitination via a bridging mechanism that facilitates physical 
interaction between Rad18 and PCNA. 
 
2.5. Polη-induced PCNA-Ub is dissociable from catalytic 
activity  
To test whether DNA polymerase activity was required for Polη to promote 
PCNA monoubiquitination, we generated a Polη mutant harboring 4 inactivating 
point substitutions in conserved residues necessary for catalytic activity140 (Figure 3-
5 A). Catalytically-inactive mutant Polη (Polη-C.I) and wild-type Polη both 
stimulated PCNA monoubiquitination to similar levels (Figure 3-5 B). Additionally, 
Polη-C.I. caused Rad18 redistribution to nuclear foci in a manner nearly identical to 
Polη-WT (Figure 3-5 C, D). Thus, the function of Polη in promoting Rad18-
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mediated PCNA monoubiquitination is dissociable from its catalytic role as a DNA 
polymerase. 
To probe the molecular determinants of PCNA monoubiquitination induced 
by Polη, we performed structure-function studies using Polη truncation mutants that 
progressively eliminated AAs 1-400 spanning the catalytic domain (Figure 3-5 A). 
Interestingly, when expressed at equal levels, the Polη-truncation mutants mobilized 
Rad18 to nuclear foci in a manner similar to Polη-WT (Figure 3-5 E). A Polη 
truncation constituting only 300 C-terminal amino acids induced a level of PCNA 
monoubiquitination comparable to WT-Polη (Figure 3-5 F). Therefore, the Rad18- 
and PCNA-binding C-terminus of Polη represents the minimal domain that is 
necessary and sufficient to regulate Rad18 activity and promote PCNA 
monoubiquitination. 
Recent work identified a novel PIP box and UBZ-containing protein termed 
‘Spartan’ that promotes PCNA monoubiquitination via a bridging mechanism 
between PCNA and Rad18, similar to that which we have defined for Polη.161 To 
compare the relative contribution of Spartan and Polη to Rad18-mediated PCNA 
monoubiquitination, we expressed FLAG-Polη or FLAG-Spartan in H1299 cells. 
When expressed at comparable levels, Polη induced an increase in PCNA 
monoubiquitination that was nearly 10-fold higher than that conferred by Spartan 
(Figure 3-5 G) and siRNA-mediated knockdown of Polη decreased UV-induced 
PCNA monoubiquitination significantly more than Spartan knockdown (Figure 3-5 
H compare lanes 4 and 6). Together, these data indicate that scaffolding of PCNA and 
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Rad18 by Polη plays an important role in the regulation of PCNA 
monoubiquitination. 
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Figure 3-5. Physical bridging of Rad18 and PCNA by Polη is dissociable from its DNA 
Polymerase activity. 
(A) Schematic of Polη-WT (top); full-length catalytically-inactive Polη, Polη-C.I, in which 
amino acids D13, E22, D115, and E116 are mutated to alanine; and N-terminal Polη truncation 
mutants, Polη-Δ(301-713) and Polη-Δ(401-713). 
(B) Immunoblots of fractionated lysates from Myc-Polη-WT or Myc-Polη-C.I.-expressing 
H1299 cells that were treated with UV (10 J/m2) or sham-irradiated. 
(C) Representative images of CSK-extracted nuclei from H1299 cells that were co-infected 
with CFP-Rad18 and empty control adenovirus (left), Myc-Polη-WT (middle), or Myc-Polη-
C.I. (right) and treated with UV (10 J/m2) or sham-irradiated. Scalebar = 10 um. 
(D) Quantification of CFP-Rad18 foci-positive nuclei as a percentage of CFP-Rad18-
expressing H1299 cells expressing empty control adenovirus, Myc-Polη-WT, or Myc-Polη-C.I. 
**, p=0.0016; *, p=0.0287; Error bars = SEM. 
(E) Quantification of CFP-Rad18 foci-positive nuclei as a percentage of CFP-Rad18-
expressing H1299 cells expressing empty control adenovirus, Myc-Polη-WT, Myc-Polη-
Δ(301-713), or Myc-Polη-Δ(401-713). Error bars = SEM. 
(F) Immunoblot of fractionated lysates from H1299 cells expressing empty control adenovirus, 
Myc-Polη-WT, Myc-Polη-Δ(301-713), or Myc-Polη-Δ(401-713). 
(G) Immunoblot of fractionated lysates from H1299 cells expressing empty vector control, 
FLAG-Polη, or FLAG-Spartan and lysed two hours after treatment with 10 J/m2 UV or sham-
treatment. 
(H) Immunoblot of fractionated lysates from H1299 cells treated with scramble control siRNA 
or siRNA against Polη or Spartan and lysed two hours after UV treatment or sham. Spartan 
knockdown was validated by depletion of co-expressed FLAG-Spartan (lanes 6-10). 
 
 
 
 
2.6. Specificity of Y-family Pol–dependent PCNA-Ub 
We next asked whether the stimulatory effect of Polη on Rad18 activity was 
shared by other Y-family TLS Polymerases. Similar to Polη, Polκ associates with 
Rad18,141 redistributes to form nuclear foci in response to DNA damage, and 
associates with PCNA via C-terminal PIP box. Therefore, for the purpose of 
comparison with Polη, we determined the effects of manipulating Polκ expression 
levels on PCNA monoubiquitination. In contrast with Polη knockdown, Polκ 
depletion did not attenuate PCNA monoubiquitination basally or after genotoxin 
treatment (Figure 3-6 A). Even when expressed at levels approximately 15-fold 
higher than Polη, Polκ did not induce the robust PCNA monoubiquitination response 
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elicited by Polη (Figure 3-6 B). Polκ also exhibited induced far less Rad18 
redistribution to chromatin. Hence, the role of Polη in promoting genotoxin-induced 
PCNA monoubiquitination is not shared by all Y-family TLS polymerases. 
Because Polη and Polκ both associate with Rad18 after DNA damage,80, 141 
differences in Rad18 binding do not explain the inability of Polκ to promote PCNA 
monoubiquitination. We therefore hypothesized that differences in TLS Polymerase-
PCNA binding account for the differential contributions of Polη and Polκ to PCNA 
monoubiquitination. Domains flanking the PIP boxes in the various Y family 
members confer dramatically different PCNA-binding affinities;175 specifically, the 
high PCNA-binding affinity of Polη relative to other TLS Polymerases is attributed in 
large part to the ‘PLTH’ sequence immediately C-terminal to its PIP-box  (Figure 3-6 
C). 
To test whether PCNA-binding affinity influences relative PCNA 
monoubiquitination activity, we performed domain-swap experiments in which we 
removed the PLTH motif from Polη (generating Polη-ΔPLTH) or added it to Polκ 
(generating Polκ+PLTH) (Figure 3-6 C). We then compared the subcellular 
distribution of wild-type and mutant forms of Polη and Polκ. As expected, Polη-
ΔPLTH showed reduced nuclear focus formation and was also compromised for 
PCNA monoubiquitination activity relative to Polη-WT (Figure 3-6 D-F). 
Conversely, whereas Polκ-WT was localized diffusely throughout the nucleus, 
Polκ+PLTH showed a focal distribution pattern more similar to that of Polη-WT. 
Interestingly, Polκ+PLTH induced more robust PCNA monoubiquitination than Polκ-
WT (Figure 3-6 F), demonstrating that addition of the PLTH (from the Polη PIP) to 
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the Polκ PIP increases its ability to induce PCNA monoubiquitination. Therefore, 
high affinity binding of Polη to PCNA confers the unique ability among Y-family 
polymerases to promote PCNA monoubiquitination. 
DNA damage-induced PCNA monoubiquitination contributes to the PCNA-
binding of all Y-family TLS polymerase.93, 94, 151 We hypothesized that Polη would 
influence other Y-family TLS polymerases by facilitating PCNA monoubiquitination, 
independently of its catalytic activity. Therefore, we compared the UV-inducible 
redistribution of Polι and Polκ in parental XPV cells or XPV cells reconstituted with 
Polη-WT or Polη-C.I.   Consistent with prior studies,97, 176 we found that basal and 
UV-induced Polι and Polκ redistribution to nuclear foci was higher in Polη-WT-
reconstituted XPV cells compared to the Polη-defective parental cell line (Figure 3-6 
G, H). Importantly, we found that Polη-C.I. dramatically increased both basal and 
UV-induced redistribution of Polι and Polκ to nuclear foci. We conclude that cells 
expressing full-length, catalytically inactive Polη retain Rad18-stimulatory activity, 
which in turn promotes recruitment of alternative error-prone polymerases to stalled 
replication forks. 
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Figure 3-6. High-affinity interaction with PCNA drives Polη-specific induction of PCNA 
monoubiquitination. 
(A) Immunoblot of fractionated lysates from control or Polκ-depleted H1299 cells that were 
lysed 2 hours after treatment with UV (10 J/m2) or sham irradiation. 
(B) Immunoblot of fractionated lysates from H1299 cells expressing YFP-Polη or GFP-Polκ 
and lysed 2 hours after treatment with UV (10 J/m2) or sham-irradiated. 
(C) Sequence of the C-terminus of Polη and Polκ and the mutants used in domain-swap 
experiments: Polη-ΔPLTH and Polκ+PLTH. PIP-box consensus amino acids are in bold, where 
ψ = I/L/M; θ = Y/F.  
(D) Representative images of CSK-extracted nuclei from H1299 cells that were infected with 
GFP-Polκ-WT, GFP-Polκ+PLTH, YFP-Polη-WT, or YFP-Polη-ΔPLTH and treated with 10 
J/m2 UV or sham-irradiated. Scalebar = 10 µm. 
(E) Quantification of foci-positive nuclei as a percentage of H1299 cells expressing in YFP-
Polη-WT, YFP-Polη-ΔPLTH, GFP-Polκ-WT, or GFP-Polκ+PLTH. *, left p=0.0001; **, 
p=0.0004; Error bars = SEM. 
(F) Immunoblot of fractionated lysates from H1299 expressing YFP-Polη-WT, YFP-Polη-
ΔPLTH, GFP-Polκ-WT, or GFP-Polκ+PLTH. 
(G) Representative images of CSK-extracted nuclei from XPV cells that were co-infected with 
CFP-Polι or GFP-Polκ and empty control adenovirus (left), Myc-Polη-WT (middle), or Myc-
Polη-C.I. and treated with UV (10 J/m2) or sham-irradiated. Scalebar = 10 um. 
(H) Quantification of CFP-Polι foci-positive nuclei as a percentage of CFP-Polι-expressing 
XPV cells (left) and GFP-Polκ foci-positive nuclei as a percentage of GFP-Polκ-expressing 
XPV cells (right), after co-infection with empty control adenovirus, Myc-Polη-WT, or Myc-
Polη-C.I. and treatment with UV (10 J/m2) or sham-irradiation *, left p=0.0009; **, p=0.0004, 
*, right p=0.0022; Error bars = SEM. 
f Polη-WT (top); full-length catalytically-inactive Polη, Polη-C.I, in which amino acids D13, 
E22, D115, and E116 are mutated to alanine; and N-terminal Polη truncation mutants, Polη-
Δ(301-713) and Polη-Δ(401-713). 
 
 
2.7. p53 promotes PCNA monoubiquitination through Polη  
Because Rad18-mediated PCNA monoubiquitination was sensitive to Polη 
expression, it was of interest to determine relative levels of Rad18 and Polη within 
cells. Therefore, we expressed an in-frame fusion of full-length Polη and full-length 
Rad18 in cultured cells, which allowed us to perform quantitative comparison of each 
endogenous protein relative to the Rad18-Polη fusion (Figure 3-7 A) using 
appropriate antibodies. 
At expression levels comparable to endogenous Polη, the Rad18-Polη fusion 
protein was nearly undetectable in immunoblots with anti-Rad18 antibody (Rad18 
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light), and prolonged exposures revealed that expression of the fusion at these levels 
was substantially lower than endogenous Rad18 (Rad18 dark). This surprising result 
demonstrated that cellular Rad18 protein expression is several orders of magnitude 
higher than Polη in human cells; we estimate that Rad18 expression exceeds Polη by 
approximately 75-fold. Importantly, expression of the Rad18-Polη fusion protein to a 
level double that of endogenous Polη (and negligible compared to endogenous 
Rad18) induced a six-fold increase in PCNA monoubiquitination (right lane), 
showing that Rad18-mediated PCNA monoubiquitination is highly sensitive to Polη 
levels. These findings prompted us to determine whether physiologically-relevant 
changes in Polη expression influence PCNA monoubiquitination. 
POLH is a transcriptional target of activated p53 and DNA damage stimulates 
p53-dependent increases in Polη protein expression.177 Because endogenous Polη 
levels are limiting for Rad18 activity, we hypothesized that p53-induced Polη 
expression contributes to PCNA monoubiquitination. Therefore, we compared UV-
induced PCNA monoubiquitination in WT HCT-116 cells and an isogenic p53-null 
HCT-116 line (Figure 3-7 B). As expected, Polη protein levels were lower in p53-
null cells (compared to WT) after UV. Interestingly, PCNA was monoubiquitinated 
after UV-treatment in a manner that was temporally co-incident with Polη expression 
in p53-expressing HCT-116 cells, but not in p53-/- cells. 
To test whether the p53-induced PCNA monoubiquitination was Polη-
dependent, we depleted Polη in p53-null H1299 cells that were transfected with 
empty-vector or pcDNAp53. As shown in Figure 3-7 C, transient expression of p53 
led to concomitant increases in Polη expression and UV-induced PCNA 
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monoubiquitination (compare lanes 1 & 2 with 5 & 6). Importantly, Polη depletion 
severely impaired PCNA monoubiquitination in p53-expressing cells compared to 
controls. Therefore, the p53-dependent component of PCNA monoubiquitination is 
Polη-mediated. 
Because loss of p53 sensitizes normal fibroblasts, but not XPV cells, to UV,178 
179 we hypothesized that the UV protection conferred by Polη is mediated by p53. To 
test this hypothesis, we compared UV survival in p53-depleted HDF cells infected 
with ‘empty’ control adenovirus or adenovirus expressing Polη at levels that confer 
UV-survival in XPV fibroblasts (see Figure 2-1). We found that Polη-expression 
modestly but significantly increased UV survival in p53-/- cells (Figure 3-7 D). 
Therefore, loss of p53-mediated Polη regulation indeed contributed to the UV 
sensitivity of p53 null fibroblasts. Together, these results suggest that Polη facilitates 
PCNA monoubiquitination in a p53-dependent manner, thereby revealing a novel link 
between the p53 pathway and TLS (Figure 3-8). 
 
  
 
69 
 
Figure 3-7. Rad18-Polη interaction is checkpoint sensitive and p53-regulated in response to DNA 
damage. 
(A) Immunoblots of fractionated lysates from H1299 cells transfected with increasing 
quantities of pACCMV-Rad18-Polη fusion construct. 
(B) Immunoblot of fractionated lysates from HCT-116 WT or HCT-116 p53-/- cells that were 
UV-treated (30 J/m2) and lysed at indicated times after irradiation. 
(C) Immunoblots of fractionated lysates of H1299 cells that were transfected with empty 
pcDNA as control or pcDNA-p53, followed by non-targeting control siRNA or siRNA against 
Polη. Cells were lysed 6 hours after 10 J/m2 UV. 
(D) UV-sensitivity of WT or p53-/- HDF incubated in 1mM caffeine and exposed to increasing 
doses of UV. Cells were infected with YFP-Polη adenovirus at a dose that confers UV-survival 
in XP115LO cells (see Supplementary Fig. S6). **, p=0.0305 at 12 J/m2.**, p=0.0036 at 15 
J/m2. 
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Figure 3-8. Contributions of p53 and Chk1 signaling to Polη-facilitated PCNA 
monoubiquitination. 
UV-induced p53 activity leads to transcriptional induction of Polη expression (left). RPA-
coated ssDNA generated through helicase-polymerase uncoupling directly recruits Rad18 and 
promotes Polη-Rad18 association via Chk1 signaling (right), thereby stimulating PCNA 
monoubiquitination and dependent DDR pathways. 
 
3. Discussion 
The results described here are consistent with existing models of TLS 
pathway activation involving an initial redistribution of the Rad18-Polη complex to 
the vicinity of damaged DNA (most likely via association of Rad18 with RPA-coated 
ssDNA).102, 180 However, our results extend current models in that we propose Rad18 
is in turn targeted to PCNA, its relevant substrate at the stalled replication fork, by 
Polη (Figure 3-8). Specifically, the extreme C-terminus of Polη physically bridges 
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Rad18 and PCNA to stimulate PCNA monoubiquitination (Figure 3-4), a function 
unique to Polη among TLS polymerases and fully dissociable from its TLS 
polymerase activity. The results of this study challenge the notion that TLS 
constitutes a simple linear pathway in which Rad18 acts upstream of Polη to promote 
TLS. Instead, we propose that Rad18 and Polη play mutually-dependent roles in TLS 
pathway activation. 
Non-catalytic effector functions have been identified for other participants of 
the DDR, including Rev1,181 Rad18,86 NBS1,182 and Chk1,81 but this is the first 
demonstration of a DNA polymerase-independent activity for Polη. A non-catalytic 
role for Polη in stimulating PCNA monoubiquitination helps explain results of recent 
studies by other labs. For example, XPV cells are hypersensitive to BPDE and other 
genotoxins whose DNA lesions are not bypassed by Polη;166, 167 clearly, a 
polymerase-independent function of Polη that promotes PCNA monoubiquitination 
and activation of Polκ (the TLS polymerase that mediates bypass of BPDE adducts) 
explains the BPDE-sensitivity of XPV cells. In other studies, catalytically-dead Polη 
mutants conferred DNA damage tolerance,169, 183 and mutagenesis.168, 169 Because 
PCNA monoubiquitination at K164 is necessary for tolerance of UV and other 
genotoxins,98, 153, 154 restoration of UV-survival by catalytically-dead Polη169 is 
explained by its scaffold function that promotes PCNA monoubiquitination, thus 
recruiting other TLS polymerases that facilitate tolerance, albeit at a cost of increased 
mutagenesis. 
The Polη scaffolding function identified here has important implications for 
the molecular basis of genetic instability in XPV patients. Mutagenesis in XPV cells 
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is widely believed to result solely from deficient Polη polymerase activity,184 leading 
to error-prone TLS of UV-damaged DNA by alternative and inappropriate TLS 
polymerases.118 Many XPV mutations encode C-terminally-truncated forms of Polη 
that lack Rad18- and PCNA-binding domains.171 However, in XPV cells in which 
Polη catalytic activity is perturbed while Rad18-PCNA bridging activity remains 
intact, high rates of UV-induced mutation frequencies may be conferred not only by 
loss of thymine dimer bypass activity by Polη, but also by stimulation of Rad18-
mediated PCNA monoubiquitination and recruitment of alternative error-prone DNA 
polymerases. 
Our finding that cellular Rad18 expression vastly exceeds Polη was 
unexpected, yet fully explains why PCNA monoubiquitination is exquisitely sensitive 
to slight alterations in Polη levels (Figure 3-7). Potentially, any process that affects 
Polη expression,177 stability,185-187 or nuclear localization188 or its association with 
Rad18 is likely to affect PCNA monoubiquitination and in turn influence TLS. 
Indeed, we show here that transcriptional induction of POLH by p53 contributes to 
PCNA monoubiquitination. The Polη-Rad18 interaction is dependent on checkpoint 
signaling via Chk1.80 Therefore, the results of this study may explain the long-
standing observation that Chk1 signaling is required for efficient PCNA 
monoubiquitination.81, 141 In fact, the Rad18-Δ(402-445) mutant in this study that 
failed to monoubiquitinate PCNA inducibly in response to Polη expression lacks the 
Chk1-dependent phosphorylation sites required for Polη binding.80 Therefore, the 
Polη-dependent mechanism for PCNA monoubiquitination described here may 
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provide the basis for crosstalk between TLS and multiple processes including p53 
signaling and the S-phase checkpoint. 
Several DNA damage tolerance pathways depend on PCNA 
monoubiquitination, including replication fork restart157 template switching,156 
intrastrand cross-link repair,158 and the Fanconi Anemia pathway.159 Hence, Polη 
contributes to cross-talk between multiple DDR pathways via PCNA 
monoubiquitination; loss of this element of the DDR in XPV underscores the 
importance of their orchestrated convergence to preserve genetic stability. 
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CHAPTER 4 
PHOSPHORYLATION-MEDIATED REGULATION OF POLη-DEPENDENT 
PCNA MONOUBIQUITINATION AND RAD18  
 
 
1. Checkpoint signaling and Polη-dependent PCNA 
monoubiquitination 
1.1. Introduction 
The results reported in Chapter 2 demonstrate a novel role for Polη in 
promoting DNA damage tolerance through mechanisms that are entirely dissociable 
from its well-known polymerase function. By promoting physical interaction of 
Rad18 with PCNA, Polη helps facilitate damage-induced monoubiquitination of 
PCNA and in turn initiate TLS. The exquisite sensitivity of PCNA 
monoubiquitination to changes in Polη levels (Figure 3-2) and the extent to which 
Rad18 expression levels exceed Polη (Figure 3-6) suggest that regulation of Polη 
expression contributes to regulation of PCNA monoubiquitination. Polη-dependent 
PCNA monoubiquitination is regulated at least in part by p53 (Figure 3-6), which 
transcriptionally up-regulates Polη expression after UV. However, several additional 
questions regarding the regulation of this process remain unanswered. 
Previous studies have implicated checkpoint signaling in various steps of the 
mechanism of Polη-dependent PCNA monoubiquitination described above. 
Importantly, Polη-Rad18 association has been shown to be Chk1-dependent, as a 
function of the S-phase kinase Cdc7.  
Cdc7 is required for initiation of DNA replication by phosphorylating MCM2-
7 in the pre-replication complex, thus stimulating origin firing.189 It has been shown 
 
  
 
75 
that Cdc7 is a target of S-phase checkpoint signaling pathways that block firing of 
origins.190,191 Recent evidence also shows that Cdc7 participates in recovery from 
checkpoint-mediated replication arrest, although few downstream targets of Cdc7 
have been identified.192 Rad18 is necessary for TLS of genotoxin-induced DNA 
damage and for recovery from damage-induced S-phase checkpoints.141,193 
Mechanisms that regulate Rad18 in these TLS processes are not understood. 
Phosphorylation of Rad18 takes place in parallel with Rad18 redistribution to 
stalled replication forks,101 and our lab previously found that Cdc7 phosphorylates 
Rad18 in a UV-inducible manner.80 This phosphorylation takes place at a specific 
serine (S434) in the C-terminus of Rad18, and it stabilizes Rad18-Polη associations 
and contributes to Polη translocation to sites of DNA damage.80, 142 Mutation of S434 
eliminates the UV-inducible Rad18-Polη interaction and sensitizes cells to UV 
irradiation. These data show that Rad18 is a Cdc7 target in checkpoint recovery 
pathways and led us to hypothesize that Chk1 regulates the UV-responsive 
recruitment of Polη to stalled RFs, presumably via Cdc7-mediated phosphorylation 
Rad18 (Figure 4-1). 
The results shown demonstrate a novel role for checkpoint signaling in the 
regulation of Rad18-mediated PCNA monoubiquitination. Specifically, these results 
show that Chk1 promotes UV-inducible PCNA monoubiquitination by facilitating 
physical interaction between Rad18 and Polη. Interestingly, we found that Rad18-
Polη interactions are Chk1-dependent only in the chromatin fraction of cell lysates. 
Together, these results demonstrate a novel role for checkpoint signaling in the 
activation and regulation of TLS. 
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Figure 4-1. Hypothesized regulation of Polη recruitment to stalled RFs due to 
Cdc7-mediated phosphorylation of Rad18. 
 
 
 
1.2. Results 
Based on the importance of Rad18-Polη interactions in stimulating PCNA 
monoubiquitination, we hypothesized that loss of checkpoint signaling would 
compromise PCNA monoubiquitination. Indeed, when we depleted H1299 cells of 
Chk1 using siRNA, we found that PCNA monoubiquitination was severely 
compromised, as was the chromatin-bound fraction of Rad18 (Figure 4-2). This 
finding was consistent with other reports that Chk1 mediates maximum PCNA 
monoubiquitination, albeit through kinase-independent mechanisms.81 
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Figure 4-2. Immunoblot of lysates from H1299 cells that were treated with non-
targeting control siRNA or siRNA against Chk1. 
 
To determine how Chk1 depletion compromised PCNA monoubiquitination, 
we performed co-immunoprecipitation experiments in cells expressing HA-tagged 
Rad18 that were treated with UV, fractionated after lysis, and then incubated with 
HA-coupled sepharose beads. Consistent with the finding that Chk1 drives Rad18- 
Polη interactions, Chk1-depletion led to reduced co-immunoprecipitation of 
chromatin-bound Rad18 with Polη, together with attenuation of PCNA 
monoubiquitination (Figure 4-3). Interestingly, Chk1 status did not affect binding of 
co-immunoprecipitation of Rad18 and Polη from the soluble fraction, indicating that 
checkpoint signaling only regulates chromatin bound, and presumably active, states 
of Rad18 and Polη. 
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Figure 4-3. Immunoblot analysis of anti-HA precipitates from HA-Rad18-
expressing H1299 cells transfected with non-targeting control siRNA or siRNA 
against Chk1 followed by treatment with UV (10 J/m2) or sham irradiation. 
 
The results presented above show that the Polη-Rad18 interaction is 
checkpoint dependent, as expected, and that this binding is important for efficient 
PCNA monoubiquitination. However, the unexpected finding that Chk1 status only 
impacts Rad18- Polη binding in the chromatin fraction indicates that Chk1 signaling 
is involved in targeting the complex to sites of DNA damage. Most likely, Chk1-
signaling either drives translocation of the Rad18-Polη to chromatin, which would be 
consistent with the Chk1-Cdc7 kinase-dependent mechanism,80 or stabilizes the 
complex at replication forks, which would be consistent with the kinase-independent 
mechanism.81 
To distinguish between these two possibilities, we measured the redistribution 
of Rad18 to nuclear foci in the presence or absence of Chk1 signaling. When we 
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expressed CFP-Rad18 in cells treated with non-targeting control siRNA or siRNA 
against Chk1, Chk1-depletion severely compromised the UV-induced redistribution 
of Rad18 to nuclear foci (Figure 4-4 and 4-5), consistent with the reduced 
chromatin-binding of Rad18 shown in Figure 4-2. We observed similar results after 
depletion of Cdc7, a distal target of Chk1 that promotes association between Rad18 
and Polη.80 These results indicate that the kinase activity of Chk1 is involved in 
driving Rad18 redistribution to chromatin, presumably via stimulation of Rad18-Polη 
physical interaction, which recruits Rad18 to PCNA via the Polη-mediated bridging 
mechanism. The kinase-independent mechanism of stimulating PCNA 
monoubiquitination involves a platform-like mechanism, and its impact is thus 
limited to stalled forks that only affects chromatin-bound Rad18. However, the results 
of Figure 4-4 and 4-5 show that Chk1 influences translocation of Rad18 from 
soluble to chromatin, thus involving steps distal to chromatin, such as soluble Chk1 
kinase signaling. These results thus implicate the kinase activity of Chk1 in 
promoting PCNA monoubiquitination, though kinase-independent mechanism is not 
contradicted.  
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Figure 4-4. Representative images of H1299 cells expressing CFP-Rad18 and UV- or sham-
treated.  
Cell were treated with siRNA against Chk1, RPA, or non-targeting controls, 
exposed to sham or UV, and then CSK-extracted after two hours. 
 
 
 
 
Figure 4-5. Quantification of CFP-Rad18 expressing H1299 cells as a function of RPA and Chk1. 
 
 
To further distinguish between kinase dependent or independent contributions 
of Chk1 to Rad18 E3 ligase activity and PCNA monoubiquitination, we looked 
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upstream of Chk1 activation. Current models explain that Chk1 is activated after RPA 
coats ssDNA to trigger ATR/ATRIP interactions, which stimulate Chk1 kinase 
activity.64 Additionally, RPA has been reported to recruit Rad18 directly to chromatin 
via physical interaction with Rad18.102 80When we depleted CFP-Rad18 expressing 
cells of RPA with siRNA, we found that RPA-depleted cells exhibited diminished 
Rad18 redistribution after UV-irradiation, similar to Chk1-depleted cells (Figures 4-4 
and 4-5). Our demonstration that depletion of Chk1 (a distal effector of RPA in the S-
phase checkpoint) also compromises Rad18 activity in a manner similar to RPA 
indicates that RPA regulates initiation of TLS via 2 mechanisms: (1) a Chk1-
independent pathway recruiting Rad18 complexes directly to ssDNA and (2) a Chk1-
dependent mechanism that facilitates Polη-Rad18 complex formation, which 
promotes productive interactions between Rad18 and its substrate, PCNA. 
 
 
2. JNK-mediated Rad18 phosphorylation and Y family 
Polymerase activation1 
 
 
2.1. Introduction 
Improper coordination of TLS poses great risks of mutagenesis by favoring 
error-prone DNA replication, as best exemplified by XPV.194 However, the processes 
that regulate activation of TLS and physical interactions between TLS enzymes are 
                                                
1 Results presented in this section were published in in May 2012 in the following manuscript: Barkley 
LR, Palle K, Durando M, Day TA, Gurkar A, Kakusho N, Li J, Masai H, Vaziri C. c-Jun N-terminal 
kinase-mediated Rad18 phosphorylation facilitates Polη recruitment to stalled replication forks. Mol 
Biol Cell. 2012 May;23(10):1943-54. 
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poorly inderstood. Direct interplay between checkpoint signaling and TLS activation 
has been reported80, and the results shown above demonstrate coordination between 
checkpoint signaling and TLS via Chk1-dependent phosphorylation of Rad18 and 
through physical interactions with RPA. Due to the detection of numerous UV-
inducible phosphorylation sites on Rad18, we hypothesized that phosphorylation of 
Rad18 contributes to the activation of TLS and facilitates interaction with TLS 
Polymerases. Indeed, we found that Cdc7-mediated phosphorylation of Rad18 at 
serine 434 drives binding between Rad18 and Polη and contributes to tolerance of UV 
light. However, Cdc7-mediated phosphorylation at serine 434 is only one of many 
phosphorylation sites on Rad18, and we thus hypothesized that other phosphorylation 
sites may contributes to TLS activation via similar mechanisms. 
 
2.2. Rad18 is a JNK phosphorylation target 
Whereas serine 434 of Rad18 was shown to be a direct phosphorylation target 
of Cdc7, numerous other phosphorylation sites of unknown consequence were also 
identified in this same region.80 Additionally, a recent mass spectrometry-based 
screen of phosphorylation sites in proteins purified from human mitotic spindles 
identified another phosphorylation site of Rad18 at serine 409 (Figure 4-6).195 
Because this site is highly conserved among species and in the vicinity of the Cdc7 
target S434, our lab tested whether this phosphorylation event may regulate Rad18 
activity in a manner analogous to S434. 
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Figure 4-6. Rad18 is a phosphorylation target of JNK. 
A. Serine 409 phosphorylation site identified in large-scale screen of 
phosphoproteins. 
B. Comparison of sequences flanking Rad18 S409 with JNK1 consensus 
phosphorylation sites. 
C. In vitro phosphorylation of Rad18 by JNK (expt by L. Barkley). 
 
After generating phosphospecific antibodies to the phosphopeptide 
corresponding to residues 398–413 of Rad18 (Figure 4-6A), we found that S409 was 
phosphorylated in a UV-inducible manner. Similar to S434, S409 phosphorylation 
was found to be Chk1-dependent, consistent with the hypothesis that Chk1-dependent 
phosphorylation of TLS proteins links S-phase checkpoint signaling with TLS. 
However, the conserved sequences flanking S409 do not correspond to the preferred 
substrate motifs for Chk1196 and in vitro kinase assays with recombinant Chk1 and 
Rad18 elicited negligible phosphorylation at S409, together indicating that 
phosphorylation of Rad18 S409, like S434, is not mediated by Chk1. Instead, it was 
noted that the sequences flanking S409 greatly resemble the consensus sequence for 
preferred c-Jun N-terminal kinase (JNK) substrates (Figure 4-6B). In vitro kinase 
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assays with recombinant Rad18 indeed showed strong phosphorylation by JNK 
(Figure 4-6C), indicating that Rad18 is indeed a phosphorylation target of JNK. 
 
2.3. JNK-mediated Rad18 phosphorylation promotes Rad18-
Polη binding 
To determine whether Rad18 is a phosphorylation target of JNK in live cells, 
HA-tagged Rad18 was immunoprecipitated from cells treated with UV or sham 
irradiation in the presence or absence of the pharmacological inhibitor of JNK, 
SP600125. Probing with the S409 phosphospecific antibody revealed a marked 
reduction in Rad18 phosphorylation in the presence of the JNK inhibitor, indicating 
that JNK activity indeed targets Rad18 in live cells in a UV-inducible manner 
(Figure 4-7A). 
The UV-inducible nature of S409 phosphorylation drew further parallels to 
Cdc7-mediated S434 phosphorylation, which facilitates UV-dependent Rad18-Polη 
binding. To determine whether phosphorylation at S409 contributes to interaction 
with Polη, we created a mutant Rad18 in which S409 is mutated to Alanine, 
Rad18S409A (Figure 4-7B). Rad18S409A was not reactive with the p-S409 
phosphospecific antibody, as expected. When we immunoprecipitated HA-tagged WT 
or S409A Rad18 from Rad18-/- HCT-116 cells treated with sham irradiation or UV, 
we detected association only between WT-Rad18 and Polη, indicating that 
phosphorylation at S409 is important for Rad18-Polη binding (Figure 4-7C). To 
further determine whether phosphorylation at S409 drives Rad18-Polη association, 
we created a phosphomimetic substitution at S409, replacing serine with the 
negatively charged glutamic acid to yield Rad18-S409E (Figure 4-7-B). Indeed, 
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when we expressed WT, S409A, or S409E at equal levels and immunoprecipitated 
Rad18 after sham irradiation or UV, we found that basal and UV-induced association 
between Rad18-S409E was slightly greater than WT-Rad18, indicating that the 
phosphomimetic substitution at S409, though an imperfect recreating of a phosphate 
moiety, increases binding between Rad18 and Polη. Together, these results 
demonstrate that JNK-kinase mediated phosphorylation at S409 on Rad18 contributes 
to UV-inducible binding between Rad18 and Polη. 
 
 
Figure 4-7.  Serine 409 phosphorylation drives UV-inducible interaction of Rad18 with Polη. 
A. Immunoblots of lysates from H1299 cells expressing HA-Rad18 that were 
treated for 1 h with 1 µM SP600125 or left untreated for controls, followed by 
UV or sham irradiation. After 2 h, Rad18 was immunoprecipitated from cell 
extracts using HA-coupled beads, and immune complexes were resolved by 
SDS–PAGE and probed sequentially with antibodies against Rad18 pS409 and 
HA. (expt by T. Da) 
B. Sequences Rad18 Wt and the Rad18 mutants harboring alanine and glutamic 
acid substitutions at S409. 
C. Immunoblots of immunoprecipitates from RAD18−/− cells expressing HA-
Rad18 WT or HA-Rad18 S409A were treated with UV or sham irradiation and 
lysed after 6 h. Chromatin fractions from the cells were solubilized and 
immunoprecipitated with anti-HA antibodies. The resulting immune complexes 
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were resolved by SDS–PAGE and analyzed by immunoblotting with antibodies 
against Rad18 S409, HA, and Polη. 
D. Immunoblots of immunoprecipitates from RAD18−/− cells expressing HA-
Rad18 WT, HA-Rad18 S409A, or HA-Rad18 S409E that were treated with UV 
or sham irradiation and lysed after 6 h. (expt by L. Barkley) 
 
 
 
2.4. JNK-mediated Rad18 phosphorylation drives Polη to 
nuclear foci 
As demonstrated extensively in Chapter 2 of this thesis and in many previous 
reports,80, 86, 197 the cellular redistribution of Rad18 and Polη is tightly coordinated in 
cells, especially after exposure to DNA damaging agents. To determine whether JNK-
mediated phosphorylation of Rad18 contributes to the UV-inducible interplay 
between Rad18 and Polη, we measured the redistribution of Polη in cells expressing 
WT Rad18 or Rad18 S409A. Consistent with a role for Rad18 in directing UV-
inducible Polη redistribution, the percentage of cells harboring nuclear Polη foci were 
greatly increased after co-expression with WT-Rad18 (Figure 4-8A, B). However, 
Polη foci were greatly diminished in the presence of Rad18-S409A, indicating that 
JNK-mediated phosphorylation of Rad18 contributes to the Rad18-dependent 
redistribution of Polη after exposure to UV. 
Rad18 has also been shown to bind to Polκ and to contribute to its damage-
dependent redistribution to nuclear foci141, although the binding sites on the two 
proteins are completely unknown. To determine whether JNK-mediated 
phosphorylation of Rad18 contributes to mobilization of Polκ as well, we tested the 
effect of the S409A on Polκ redistribution after UV. As expected, the UV-inducible 
redistribution of Polκ was dramatically less than for Polη (compare ordinates in 
Figure 4-8 B and D) but was also diminished in the context of Rad18-S409A 
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compared to Rad18-WT (Figure 4-8D). This indicates that JNK-mediated 
phosphorylation of Rad18 does not specifically affect Rad18-Polη binding, but rather 
contributes to the Rad18-mediated mobilization of TLS Polymerases in a general 
fashion. It is of interest to test how this JNK-mediated phosphorylation is affected by 
different genotoxins (e.g. UV vs BPDE vs MMC) and how this impacts association 
with and mobilization of the different TLS polymerases. 
 
 
 
Figure 4-8.  JNK-mediated Rad18 phosphorylation contributes to UV-inducible redistribution of 
Polη. 
A. Representative images of CSK-extracted nuclei from H1299 cells that were infected 
with YFP-Polη and co-infected with empty control adenovirus, Rad18-WT, or Rad18-
S409A and exposed to UV or sham irradiation. 
B. Quantification of YFP-Polη foci-positive nuclei as a percentage of YFP-Polη-
expressing H1299 cells as a function of Rad18 status. 
C. Representative images of CSK-extracted nuclei from H1299 cells that were infected 
with GFP-Polκ and co-infected with empty control adenovirus, Rad18-WT, or Rad18-
S409A and exposed to UV or sham irradiation. 
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D. Quantification of GFP-Polκ foci-positive nuclei as a percentage of GFP-Polκ -
expressing H1299 cells as a function of Rad18 status. 
 
 
The results of Figures 4-5 through 4-8 show that JNK-mediated 
phosphorylation drives the UV-inducible binding of Rad18 and Polη, a process that is 
known to promote tolerance of UV-damaged DNA. To test whether phosphorylation 
at S409 contributes to tolerance of UV damage, we compared the UV survival of cells 
expressing WT-Rad18 or Rad18-S409A. When we depleted H1299 cells of 
endogenous Rad18 (using siRNA targeting the Rad18 3’UTR) and then 
complemented with WT-Rad18 or Rad18-S409A, we found that Rad18-S409A-
expressing cells were sensitized to UV light, compared to Rad18-WT (Figure 3-9). 
Phosphorylation of Rad18 at serine 409 by JNK thus contributes to the UV tolerance 
of cells mediated by Polη, most likely via promotion of Rad18-Polη physical 
interactions (Figure 4-7) and subsequent mobilization of Polη to replication forks 
(Figure 4-8), 
 
 
 
2.5. Discussion 
The interaction of Rad18 with Polη represents one of several mechanisms that 
facilitate recruitment of Polη to the replication machinery. It is generally believed that 
Rad18 guides Polη to sites of stalled replication86 and that Rad18-mediated Polη 
chaperone activity promotes stable engagement of Polη with PCNA via PCNA-
interacting protein (PIP) box and UBZ-mediated interactions.94 These results 
demonstrate a novel UV damage–inducible Rad18 phosphorylation site at the 
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conserved residue Serine-409 that resides in the Polη-binding domain of Rad18. S409 
phosphorylation is important for Rad18–Polη association and confers more efficient 
chaperoning of Polη to nuclear foci at sites of replication stalling, all of which 
promotes tolerance of UV-induced DNA damage (Figure 4-9). The impact and 
phenotype conferred by JNK-mediated phosphorylation at S409 greatly parallels the 
Cdc7-mediated phosphorylation at S434. Our results show that Rad18-mediated 
tolerance of UV damage requires both JNK- and Cdc7-mediated phosphorylation of 
Rad18. 
 
 
Figure 4-9. Schematic of JNK-mediated regulation of Rad18-Polη binding in 
response to UV light. 
 
These results represent the first demonstration of a relationship between JNK 
signaling and TLS. The activation of JNK in response to replication stress–inducing 
agents such as UV radiation198 and BPDE199 has been studied extensively, but 
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relationships between JNK and checkpoint signaling in the TLS response have not 
been explored. Our finding that JNK regulates TLS in a manner that is Chk1 
dependent further demonstrates the intricate coordination of the various effector 
branches of the DNA damage response, including checkpoint signaling and TLS. 
Phosphorylation of Rad18 by JNK has interesting implications. JNK is 
generally considered a mediator of apoptosis, not processes that mediate tolerance of 
DNA damage, such as TLS. It is therefore surprising that JNK promotes Rad18–Polη 
recruitment to stalled replication forks to protect against DNA damage and 
presumably apoptosis. However, JNK activity is not exclusively associated with 
apoptosis. Many stimuli that activate JNK do not lead to apoptosis, perhaps because 
of active survival signaling pathways that prevent the apoptotic response.200 In 
addition, the kinetics of JNK activation may determine whether or not there is an 
apoptotic outcome. For example, transient JNK activation (e.g., in response to 
cytokines) may mediate survival, whereas prolonged activation can mediate 
apoptosis.201  Although SAPK signaling has not previously been implicated in TLS or 
postreplication repair, recent studies by other labs have implicated JNK in control of 
DNA replication. For example, Miotto and Struhl reported that JNK phosphorylates 
Cdt1 (a replication licensing factor) on T29, leading to dissociation of HBO1 from 
replication origins and blocking DNA replication licensing.202 Similarly, Cook and 
colleagues identified multiple JNK and p38 target sites on Cdt1 the phosphorylation 
of which serves to rapidly inactivate Cdt1 and inhibit origin licensing.203 JNK thus 
helps to ensure appropriate DNA replication and genome maintenance in genotoxin-
treated cells via at least two mechanisms: inhibition of origin licensing, and the 
  
 
91 
results presented here demonstrate a role for stimulation of TLS at sites of ongoing 
DNA replication. It is of interest to determine whether additional proteins involved in 
other stages of DNA synthesis (e.g., initiation) or other modes of DNA repair are 
similarly subject to regulation by SAPKs. 
Potentially consistent with additional roles for SAPKs in DNA replication and 
repair, Lannigan and colleagues demonstrated that extracellular signal-regulated 
kinase 8 (ERK8; a SAPK family member) contains a conserved PIP box that mediates 
PCNA binding and subsequent PCNA turnover via Mdm2.204 As demonstrated in 
Chapter 2 (Figure 2-5), affinity to PCNA is crucial for activation of TLS 
Polymerases, and in general, PCNA represents a central hub for numerous DNA 
repair and replication processes. Therefore recruitment of ERK8 and perhaps 
additional PIP box–containing mitogen-activated protein kinase (MAPK) family 
members to PCNA may provide the basis for cross-talk between MAPK signaling and 
DNA replication and repair events. By analogy, JNK2 has been detected at RPA–
coated ssDNA, which both initiates checkpoint signaling that regulates TLS and 
directly recruits Rad18 to stalled forks205 (see previous section). Therefore, similar to 
ERK8, JNK2 may be able to regulate DNA replication and repair events in the 
vicinity of stalled replication forks. Further work is needed to investigate potential 
regulators and targets of the SAPKs at sites of DNA replication and repair. 
It has become increasingly evident that TLS is coordinated with other 
elements of the DNA damage response, in particular checkpoints. JNK- and DDK-
dependent Rad18 phosphorylation is clearly Chk1 dependent (Figure 4-2 through 4-
5), demonstrating further links between S-phase checkpoint signaling and TLS. The 
  
 
92 
finding that mutation of S409 to alanine influences UV-induced Polκ redistribution, 
in the context of a dramatically UV response compared to Polη, indicates that the role 
of JNK in regulating TLS may be general. Specifically, it is of interest to determine 
whether BPDE-induced Polη redistribution (which is orders of magnitude greater 
than that induced by UV) and whether sensitivity to BPDE is also influenced by JNK. 
The interaction domains for Rad18 and Polκ are yet to be determined. These results 
suggest that S409 may reside in a putative Rad18 binding domain on Polκ. 
Regarding the generality of JNK-mediated Rad18 phosphorylation, there is a 
strong precedent for phosphorylation-dependent regulation of E3 ubiquitin ligases. 
For example, sustained (but not transient) JNK signaling mediates tumor necrosis 
factor α–induced cell death via the E3 ligase Itch, which degrades the caspase 
inhibitor cFLIPL.206 Another E3 ligase, Siah2, is regulated by p38-dependent 
phosphorylation.207 Because Rad18 plays a central role in TLS, and perhaps 
additional DNA repair pathways, Rad18 phosphorylation has the potential to regulate 
multiple effector pathways, perhaps by influencing associations with its substrates 
(e.g., PCNA, RFC2, 53BP) or regulatory binding partners (e.g., Polη, Rad6, Rad5). 
Rad18 phosphorylation may serve as a molecular switch for determining various 
physiological outcomes including but not limited to TLS. 
Post-translational modification of TLS enzymes has been reported to impact 
TLS activation in several different ways. Aside from the obvious monoubiquitination 
of PCNA that coordinates stabilization of TLS polymerases in place of replicative 
polymerases, ubiquitination of Polη inhibits interaction of Polη with PCNA, thus 
regulating its ability to perform TLS.208 Polη has also been shown to be modified by 
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phosphorylation in a manner that regulates its recruitment to stalled replication 
forks.209 Additionally, the ubiquitin conjugating enzyme Rad6 is phosphorylated by 
the cyclin-dependent kinase CDK2, suggesting that Rad6 activity and potentially its 
affinity to known binding partners (e.g. Rad18) may be coordinated with cell cycle 
progression.210 Taken together, the results reports here and those of previous studies 
indicate that post-translational modification of TLS enzymes, in particular via 
phosphorylation, serves as a molecular signal to coordinate the activation of TLS with 
DNA damage sensing (RPA, Chk1), cell cycle progression (Cdc7 and CDK2), and 
potentially apoptosis (JNK). 
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CHAPTER 5 
 
ONCOGENIC SIGNALING DRIVES MISREGULATION OF TLS 
 
 
1. Introduction 
The interplay between oncogenes, DNA repair pathways, genetic stability, and 
tumorigenesis is poorly understood. Activation of the DNA damage response appears 
to function as a protective barrier to the progression of malignant transformation.129, 
211 Expression of oncogenes induces abnormal replication patterns, including re-
replication and aberrant origin firing, which causes replication stress that activates 
various arms of the DNA damage response. Replication stresses that lead to DNA 
breaks pose a great threat to genome integrity; activation of checkpoints in response 
to oncogene-induced replication stress can be considered a mechanism of protecting 
against proliferation of oncogene-expressing cells.212 213 This notion is supported by 
the observation that DSBs in precancerous lesions activate p53 and other checkpoint 
proteins, such as Chk2 and ATM, whereas cancerous lesions harbor inactivated or 
compromised DNA damage checkpoints, often due to mutation in p53 and loss of 
expression of other checkpoint proteins.129, 214  
Various arms of the DNA damage response are implicated as protective 
barriers against oncogene-induced replication stress, but the role of TLS has never 
been considered in this context. Many lines of evidence suggest that TLS may play 
both protective and harmful roles in the response to oncogene-induced replication 
stress. Putative protective roles for TLS involve permitting normal replication to 
continue in the wake of replication stress, thus avoiding persistence of stalled 
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replication forks and subsequent progression to DNA breakage. Deleterious roles 
involve over-activation of error-prone TLS that leads to mutagenesis, a concept that is 
consistent with the mutator phenotype of malignant cells. 
Various lines of evidence link error-prone replication to a mutator phenotype 
in cancer.215 For example, activating mutations in the low-fidelity base excision repair 
enzyme Polβ have been associated with mutagenesis in various cancers.216, 217  Even a 
mild over-production (4-7 fold) of Polβ causes up to an 8-fold increase in mutation 
rate.126 Upregulation of the Y-family polymerase Polκ confers a similar mutator 
phenotype.218 Considering that both Polη and Polι are substantially more mutagenic 
than Polβ and Polκ, it is reasonable to hypothesize that their overexpression may also 
confer a similar, if not more dramatic, mutator phenotype (Table 5-1). Importantly, 
studies in cultured human fibroblasts have found that the mutation rate is not elevated 
by Polη overexpression; however, these cells contain intact checkpoints that help 
protect against the mutagenic potential of overexpressed Polη.219 Because pre-
malignant cells and especially oncogene-expressing cells lack intact DNA damage 
and cell cycle checkpoints, misregulation and/or overexpression of TLS polymerases 
is likely to induce a mutator phenotype in the context of oncogene expression. 
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Table 5-1. Properties of select eukaryotic polymerases.126 
Polymerase Substitution error rate(X10-5) Normal function 
α 9.6 Replication 
δ <1.3 Replication 
ε <0.2 Replication  
β  67 BER 
ζ 110 TLS 
η 3500 TLS 
ι 7200 TLS 
κ 580 TLS 
 
The studies described in this section are intended to address the hypothesis 
that TLS plays a role in the tolerance of replication stress induced by oncogenic 
signaling. Specifically, the studies are intended to test how the expression and 
activation of TLS enzymes are affected by oncogenic signaling, how TLS contributes 
to survival and genome integrity in the presence of oncogenic signaling, and how loss 
of TLS impacts models of tumorigenesis in vivo. 
 
2. Results 
 
2.1. TLS is activated differently by different oncogenes 
To test the hypothesis that TLS is activated in the context of oncogenic 
signaling, we studied the effect of expressing a panel of oncogenes in a non-
transformed human diploid fibroblast cell line (Table 5-2 and Figure 5-1). Each of 
these oncogenes is reported to induce replication stress or activate a DNA damage 
response.220-222 Additionally, we overexpressed the replication licensing factor Cdt1 
and depleted cells of geminin. During the G1 phase of the cell cycle, DNA synthesis 
begins after the MCM complex is loaded to origins of replication by Cdt1; 
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overexpression of Cdt1 causes aberrant MCM loading and subsequent re-licensing of 
origins and re-replication,203 which lead to replication stress that promotes genome 
instability and tumorigenesis in a manner similar to oncogenes.223, 224 Geminin 
physically binds to Cdt1 and blocks its interaction with MCMs,225 thus counteracting 
the activity of Cdt1 to inhibit MCM loading and origin licensing. Gemenin depletion 
thus phenocopies Cdt1 overexpression to result in replication stress, such as re-
replication.223 
 
Table 5-2. Properties of oncogenes and replication proteins considered 
in this study.  
Gene Mechanism of action Cellular Functions Effect of overexpression  
Myc Transcription factor Metabolism, protein biosynthesis, cell cycle regulation, cell adhesion 
 Replication stalling, re-
replication, ROS226 
Ras GTPase, signal transduction via MAPK 
Cell polarity, proliferation, 
Differentiation, adhesion, migration, 
and apoptosis 
Replication stress, re-
replication227 
CycE Cdk2 binding and activation, S-phase entry Cell cycle progression 
Chromosome instability 
228  
Cdt1 MCM loading  Replication licensing, cell cycle Re-replication 
Geminin Inhibition of Cdt1 Replication licensing, cell cycle Re-replication (due to depletion) 
 
 
 Unexpectedly, markers of TLS activation were vastly different after 
expression of these oncogenes or alteration of Cdt1 and geminin expression. As 
shown in Figure 5-1, Myc and Cdt1, which are reported to activate checkpoints via 
several mechanisms, including re-replication and replication stalling,229, 230 induced 
negligible Chk1 phosphorylation and PCNA monoubiquitination compared to UV-
treated cells. Conversely, Cyclin E induced a massive PCNA monoubiquitination and 
moderate Chk1 phosphorylation, whereas Ras induced massive Chk1 
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phosphorylation, consistent with published reports,220 but only moderate PCNA 
monoubiquitination. Interestingly, depletion of the replication licensing protein 
geminin, caused Chk1 activation but failed to cause PCNA monoubiquitination.  
 
 
Figure 5-1. Expression of different oncogenes affects TLS differently. 
HDF cells were infected with empty-control adenovirus or low (+, 5.0EE9 vir/ml) and 
high (++, 1.0EE10 vir/ml) doses of different oncogenes and lysed 48 hours later. 
 
These results indicate that activation of checkpoints and TLS are not always 
coordinated in the context of oncogenic signaling and that expression of oncogenes or 
manipulation of licensing proteins activate checkpoints and TLS very differently. 
 
2.2. Cyclin E and Ras activate TLS 
We next asked how effector proteins in the checkpoint and TLS pathways 
impact the cellular response to replication stress induced by oncogenic signaling. The 
results in Figure 5-1 indicated that Cyclin E and Ras cause the greatest activation of 
TLS as demonstrated by PCNA monoubiquitination, whereas Myc had a relatively 
negligible effect on PCNA monoubiquitination. To test how TLS and checkpoints 
coordinate a response to these oncogenes, we depleted HDF cells of Rad18 or Chk1 
using siRNA (or treated cells with non-targettng siRNA for control) and then 
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expressed Myc, Ras, or Cycln E using adenovirus. Consistent with Figure 5-1, 
expression of CycE and Ras induced more monubiquitination of PCNA than Myc, 
and this effect was entirely eliminiated after depletion of Rad18, showing that 
oncogene-induced PCNA monoubiquitination was mediated by Rad18 (Figure 5-2). 
Depletion of Rad18 greatly potentiated the oncogene-induced phosphorylation of 
Chk1, especially that induced by Ras. Conversely, depletion of Chk1 had virtually no 
effect on PCNA monoubiquitination induced by Myc and Ras but greatly attenuated 
Cyclin E-induced PCNA monoubiquitination. Interestingly, expression of Myc 
induced an approximately ten-fold inrcease in  binding of NBS1/p95 to chromatin, in 
a manner that was largely independent of Rad18 or Chk1, indicating that Myc-
induced replication stress activates NBS1-dependent stress tolerance pathways, such 
as those induced by double-strand breaks. 
 
Figure 5-2. Impact of TLS and checkpoints in the response to different oncogenes. 
HDF cells were treated with non-targeting control siRNA, or siRNA against Rad18 
or Chk1 and then infected with adenovirus expressing the indicated oncogenes 
followed by lysing and fractionation 48 hours after infection with the oncogene 
viruses. 
 
  
 
100 
These results show that expression of Cyclin E and Ras, but not Myc, 
potentially activate TLS via PCNA monoubiquitination, a process dependent upon the 
recruitment of Rad18 to stalled replication. We thus tested whether expression of 
these oncogenes would result in Rad18 redistribution to nuclear foci. Consistent with 
the effect on PCNA monoubiquitination shown in Figure 5-1 and 5-2, Ras- and 
Cyclin E-expressing cells exhibited increased CFP-Rad18 redistribution to nuclear 
foci, whereas Myc had a slightly inhibitory effect on Rad18 redistribution (Figure 5-
3, A & B). Recruitment of Polη to stalled replication forks is stimulated by Rad18-
mediated PCNA monoubiquitination and represents activation of TLS. As shown in 
Figure 5-3, Ras and Cyclin E induced a three- and seven-fold increase in Polη 
nuclear foci formation, indicating that these oncogenes indeed lead to activation of 
TLS. 
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Figure 5-3. Oncogene-induced redistribution of Ra18 and Polη to nuclear foci. 
A. HDF cells were treated adenovirus expressing CFP-Rad18 or YFP-Polη followed 
by infection with empty-vector control, Ras, myc, or Cyclin E adenovirus and imaged 
live 48 hours later. B. Quantification of foci-positive cells as a fraction of total 
chromophore-expressing cells. 
 
 
 
 
2.3. TLS and Checkpoints drive tolerance of oncogenic stress  
 
To test whether the oncogene-induced activation of Rad18 and Polη shown in 
Figures 5-1 - 5-3 contributes to tolerance of oncogene-induced replication stress, we 
measured the survival of oncogene-expressing HDF cells after depletion of Rad18 
and Polη. As shown in Figure 5-4, depletion of Rad18 and Polη decreased the 
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survival of Cyclin E and Ras-expressing cells by approximately 20 and 15%, 
respectively, but had no effect on the survival of Myc-expressing cells. Depletion of 
Chk1 only impacted the survival of Ras-expressing cells. These results suggest that 
the markers of TLS activation demonstrated via PCNA monoubiquitination and 
Rad18/Polη redistribution to nuclear foci are indeed functionally significant to help 
facilitate survival in oncogene-expressing cells. 
 
 
 
Figure 5-4. Percent survival of oncogene-expressing cells. 
A. HDF cells were treated with non-targeting control siRNA or siRNA against Rad18, Chk1, or 
Poleta and then treated with empty vector control adenovirus or adenovirus expressing Cyclin E, 
Myc, or Ras. Percent survival compared to AdCon-expressing cells was measured 48 hours later 
by MTT. 
 
 
2.4. RNR-induced tumors and Rad18 expression in vivo 
 
The results shown in Figure 5-1 – 5-4 show that Ras and Cyclin E expression 
leads to activation of checkpoints and TLS enzymes and that this activation is 
important for survival in ongogene-expressing cells. We next asked whether 
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malignant cells demonstrate activation of TLS in vivo using a mouse model in which 
lung tumors are induced by expression of ribonucleotide reductase (RNR).231 RNR 
expression selectively causes tumor growth in lung tissue and induces reactive 
oxygen species that causes replication stress. We found that Rad18 protein expression 
was markedly increased in all RNR-induced tumors compared to normal lung, 
indicating that malignant cells in vivo up-regulate Rad18 expression, perhaps to use 
the TLS pathway to facilitate tolerance of replication stress (Figure 5-5). 
 
 
Figure 5-5. Rad18 expression is increased in RNR-induced lung tumors. 
 
 
2.5. Rad18 modulates Ras-driven tumorigenesis 
 
Figure 5-1 through 5-5 show that expression of oncogenes such as Ras affect 
expression and activity of key mediators of TLS, namely Rad18, both in cultured 
cells and in vivo. We next asked whether TLS impacts Ras-dependent tumorigenesis 
in vivo using wildtype or Rad18-/- mice. After lung-specific expression of K-Ras, all 
mice developed a large number of small lung tumors (<1mm diameter), but Rad18-/- 
mice also developed massive lung tumors (>3mm diameter) that were not present in 
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wildtype mice (Figure 5-6A, B). Surprisingly, in spite of the stark contrast in lung 
tumor histopathology, the wildtype and Rad18-/- mice demonstrated no difference in 
overall survival (Figure 5-6C). These results indicate that Rad18 status dramatically 
impacts the development and growth of Ras-induced lung tumors in vivo, through the 
mechanism behind this phenotype and its implication remains unclear. 
 
Figure 5-6. Rad18  status impacts Ras-induced tumorigenesis but not survival.  
Representative histopathological image lung tissue from Ras-expressing A. wildtype 
mouse and B. Rad18-/- mouse.  C. Survival curves of wildtype and Rad18-/- mice after 
development of Ras-induced lung tumors.  
 
 
3. Discussion 
 
Previous reports have demonstrated that expression of oncogenes induces 
replication stress that activates a DNA damage response and checkpoints.212, 229 
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However, the relationship between oncogenic signaling and TLS has never been 
explored. Several lines of evidence led us to hypothesize that TLS is activated under 
conditions of oncogenic signaling. First, oncogene-transformed cells accumulate 
mutations at a higher rate than normal cells121 and point mutations are introduced in 
large part by error-prone TLS polymerases. Next, checkpoint signaling has a 
stimulatory effect on TLS,80 and checkpoints are activated by many oncogenes.131 
Finally, TLS is utilized by cells to tolerate abnormal DNA structures and replication 
stress,232 and expression of certain oncogenes, such as Cyclin E, induces aberrant 
replication structures that results in DNA damage response.130 
The results presented above demonstrate a novel link between oncogenic 
signaling and TLS. We show that expression of certain oncogenes robustly activates 
TLS, and that checkpoint signaling may contribute to this activation. Our finding that 
different oncogenes activate checkpoints and TLS differently demonstrates that the 
mechanisms by which cells tolerate oncogene-induced replication stress differs 
between oncogenes (Figure 5-1). The affect of Ras, Myc, and Cyclin E expression on 
markers of DNA damage and TLS activation are listed in Table 5-3. Whereas Myc- 
and Ras-induced PCNA monoubiquitination appears to be checkpoint-independent, 
Cyclin E-induced PCNA monoubiquitination is clearly Chk1-dependent (compare 
PCNA-Ub in Figure 5-2, lanes 4 and 12). Conversely, Rad18 depletion has no effect 
on Cyc E-induced Chk1 phosphorylation (compare P-Chk1 in Figure 5-2, lanes 4 and 
8), but Cyc E-induced PCNA monoubiquitination is greatly attenuated after Chk1 
depletion. These results suggest that Cyc E-induced TLS activation takes place 
downstream of Chk1. Because Chk1 is most active during S-phase, a strong Chk1-
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dependence of Cyc C-induced PCNA monoubiquitination is consistent with the role 
of Cyclin E in promoting S-phase entry and cell cycle progression. 
 
 
Table 5-3. Oncogene expression and markers of checkpoint and 
TLS pathways. 
Oncogene Chk1 phosphorylation g-H2AX PCNA monoubiquitination 
Cyclin E ↑↑ ↑ ↑↑↑ 
Ras ↑↑ – ↑ 
Myc – – – 
 
 
The dramatic redistribution of NBS1 to chromatin after Myc expression, 
which is attenuated after Rad18 depletion, suggests that Myc induces double strand 
breaks of which Rad18 contributes to tolerance (Figure 5-2). Similarly, the massive 
increase in Ras-induced Chk1-phosphorylation after depletion of Rad18 indicates that 
Rad18 contributes to tolerance of Ras-mediated replications stress. The Chk1-
independence of Ras-induced PCNA monoubiquitination is consistent with cell cycle-
independent mechanisms of replication stress that are induced by Ras. 
The finding that Rad18 and Polη are necessary for cellular tolerance of 
expression of oncogenes demonstrates a physiological significance of oncogene-
induced TLS activation. The finding that loss of Rad18 and Polη compromises 
survival of Ras and Cyclin E-expressing cells but not Myc cells is consistent with the 
PCNA monoubiquitination and Rad18/Polη redistribution that are induced by Ras and 
Cyclin E but not Myc (Figures 5-2 and 5-3). Taken together, these data show that the 
TLS pathway is activated in response to different transforming oncogenes, that the 
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mechanism of TLS activation differs among oncogenes, and that TLS contributes to 
tolerance of oncogenic expression, namely Ras and Cyclin E. 
Our in vivo data provide further physiological significance to the relationship 
between TLS and oncogenic signaling. Our finding that Rad18 expression is 
increased in RNR-induced lung tumors suggests that Rad18 plays a role in the 
progression of RNR-induced malignant transformation or the tolerance of RNR-
induced replication stress (Figure 5-3). A dramatic increase in the size of Ras-
induced tumors in Rad18-/- mice compared to wildtype mice suggests that Rad18 
protects against overproliferation of Ras-transformed cells, though the mechanism for 
this phenomenon remains unknown (Figure 5-4). 
Together, these results demonstrate a novel role for TLS in the tolerance of 
oncogene-induced replication stress. Our findings describe a model in which 
expression of certain oncogenes (Ras and Cyclin E) leads to checkpoint activation 
and subsequent stimulation of Rad18-mediated PCNA monoubiquitination, which 
recruits TLS polymerases to mediate tolerance of oncogene-induced replication stress 
(Figure 5-7). This TLS activation promotes survival of oncogene-expressing cells, 
which carries therapeutic implications for potentially inhibiting the TLS pathway to 
decrease survival of oncogene-expressing cells. Rad18 expression clearly impacts the 
development and proliferation of malignantly transformed cells, such as RNR-
induced and Ras-induced lung tumors, but the mechanisms through which Rad18 
impacts tolerance of replication stress in these malignantly transformed cells requires 
further study. 
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Figure 5-7. TLS promotes tolerance of oncogene-induced replication stress.  
Expression oncogenes, such as Ras and Cyclin E, activates checkpoints and 
stimulates Rad18-mediated PCNA monoubiquitination, both of which stimulate TLS 
at sites of replication stress and promote cellular survival.  
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CHAPTER 6 
 
FUTURE DIRECTIONS AND CONCLUSIONS 
 
 
1. Future Directions 
 
1.1. Mutagenesis in the context of catalytically inactive Polη  
The results of Chapter 3 show that Polη drives Rad18-medited PCNA 
monoubiquitination via physical bridging of Rad18 and PCNA (Figure 3-3), a 
process that is entirely independent of its catalytic activity (Figure 3-4). Importantly, 
we found that expression of a catalytically-inactive mutant of Polη in XPV cells 
drives the recruitment of inappropriate polymerases, Polι and Polκ to stalled 
replication forks both basally and in response to UV damage (Figure 3-5). This 
important finding suggests that inappropriate, error-prone TLS of CPD or of 
undamaged DNA by Polι and Polκ will caused increased mutagenesis in cells 
expressing catalytically inactive Polη (Figure 6-1), consistent with the finding that 
Polι accounts for a large percentage of error-prone TLS in Polη-deficient XPV cells. 
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Figure 6-1. Hypothesized increased mutagenesis in the context of catalytically inactive Polη. 
In XPV cells harboring a truncated Polη, residual but limited monoubiquitination of 
PCNA leads to limited recruitment of error-prone polymerases (bottom). But in XPV cells 
expressing catalytically inactive, full-length Polη, stimulation of Rad18-mediated PCNA 
monoubiquitination in the absence of Polη-mediated lesion bypass leads to excessive 
recruitment of error-prone polymerases (top). 
 
It has been shown in MEFs169 and in yeast168 that complementation of Polη-
defeicient cells with catalytically inactive Polη leads to a higher mutation rate than in 
uncomplemented cells, but this experiement has not been demonstrated in human 
cells. Importantly, many XPV patients express full-length, catalytically inactive 
Polη;171 one may thus hypothesize that mutagenesis in their cells would be worse than 
in complete Polη null cells. 
These experiments should be performed in two ways. In the first, one may use 
gapped plasmid SupF shuttle vector assays that are based on SV40 T antigen-
dependent replication of the SupF plasmid in human cells.233, 234 Briefly, XPV cells 
that are transfected with emptry vector control, wildtype Polη, or catalytically 
inactive Polη are co-transfected with pSP189 plasmid that has been UV irradiated. 
The pSP189 is then recovered from the cells 48 hours later, digested with Dpn1 to 
remove unreplicated plasmid, and transformed into an indicator bacterial strain 
(MBM7070) containing an amber mutation in the β-galactosidase gene, and the 
transformed bacteria plated on agar containing isopropyl-1-thio-b-D-
galactopyranoside (IPTG) and X-gal. The mutation frequency is determined as the 
ratio of white (mutant) to total (blue & white) colonies that form. 
Next, determination of mutation rate may be performed using whole exome 
sequencing on the Illumina platform. Briefly, this approach involves UV-irradiating 
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XPV cells that have been transfected with empty vector control plasmid, wildtype 
Polη, or catalytically inactive Polη and then recovering DNA from these cells using 
standard phenol/chloroform extraction techniques. The DNA is then sonicated, 
labeled via PCRwith barcode-tagged primers, enriched for exome DNA by PCR, and 
sequenced on the Illumina platform. This method is preferable to the SupF assay as it 
measures mutational events on nuclear DNA, rather than cytosolic plasmids, and is 
thus a better representation of actual processes at chromatin within cells. 
We hypothesize that catalytically inactive Polη-expressing XPV cells will 
show a significantly higher mutation frequency than control-transfected XPV cells. 
These experiments will determine whether the mutagenic model shown in Figure 5-3 
is valid and will demonstrate the phenotypic significance of the polymerase-
independent function of Polη illustrated in Chapter 2. 
 
1.2. Contribution of TLS and Oncogene-induced Mutagenesis  
As outlined in the introduction and in Chapter 5, mutations play a 
fundamental role in the development and progression of cancer. Activating mutations 
in oncogenes or inactivating mutations in tumor suppressor genes can lead to 
initiation of carcinogenesis, and malignant cells exhibit subsantially higher rates of 
mutations121 and gene amplification122 than normal cells. This evidence suggests that 
malignant cells exhibit defective genome maintenance progresses, and, importantly, 
that cellular pathways that contribute to mutagenesis may be upregulated or mis-
regulated in cancer cells. 
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Considering the role that TLS plays in the introduction of point mutations, it is 
therefore plausible to hypothesize that TLS may be activated or mis-regulated in the 
context of oncogenic signaling (Figure 6-2). This was the rationale for the 
experiments described in Chapter 5, and the results shown therein are consistent with 
such a hypothesis. However, those results show that certain oncogenes contribute to 
TLS activation and not that such oncogene-induced activation of TLS actually drives 
mutagenesis. This future aim is based on the hypothesis that mutagenesis in the 
context of oncogenic signaling is due to the activity of TLS. It will use the same 
techniques described in the previous section, except that mutagenesis will be 
measured in the context of oncogene expression in the presence or absence of key 
TLS enzymes. 
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Figure 6-2. Hypothetical models of oncogene-induced activation of TLS that results in 
mutagenesis. 
 
Two main experimental approaches should be explored. The first involves 
using HDF cells that have been depleted of Rad18 or Polη, which are then infected 
with oncogene-expressing adenovirus, as outlined in Chapter 5. 48 hours post-
infection, the cells are harvested for DNA and subjected to Illumina sequencing. 
Mutation rates in cells with and without TLS enzymes are compared. The second 
approach involved repeating the same experiment in XPV cells that have been 
reconstittued with Polη or empty vector control before infection with oncogenes. 
Should either of these two approaches demonstrate a role for TLS in oncogene-
induced mutagensis, additional manipuilations of specific TLS polymerases, 
including knockdown of other TLS polymerases, may help elucidate the roles played 
by each polymerase in the introduction of mutations. That is, these experiments will 
determine which polymerase is primarily responsible for introducing point mutations, 
and if the selection of polymerase differs for different oncogenes. 
Together, these experiments will not only reveal whether the activation of 
TLS reported in Chapter 5 indeed contributes to error-prone replicaiton in the context 
of oncogenic signaling, but they will also shed light on the mechanisms of 
mutagenesis induced by oncogenic signaling and how this contributes to initiation of 
malignancy. 
 
 
  
 
114 
1.3. Damage-specificity of TLS Pol recruitment to DNA 
damage sites  
Replication by error-prone TLS Polymerases carries a high risk for 
introducing mutations and is thus a crucial step in carcinogenesis after exposure to 
environmental genotoxins. Because each TLS Pol performs accurate bypass for a 
specific lesion (ie Polη for UV CPDs and Polκ for BPDE adducts), utilization of the 
appropriate polymerase is an important means of preventing mutagenic TLS. 
However, it is not known what mechanisms are responsible for TLS Pol selection, 
nuclear translocation, and engagement with the replication machinery. 
While Rad18 has a dual role in Polη recruitment (chaperone and PCNA-Ub 
ligase), mechanisms of recruitment for the other TLS Pols (Polι, Polκ and Rev1) are 
poorly understood. For example, it is unknown whether Rad18 has chaperone activity 
for TLS Pol members other than Polη. We have devised two hypothetical models 
describing our hypotheses of TLS Pol selection for TLS (Figure 6-3): (A) Rad18-
mediated chaperoning promotes recruitment of all TLS polymerases; (B) Rad18-
mediated chaperoning (induced by Cdc7 phosphorylation of Rad18) specifically 
affects Rad18-Polη recruitment. Future studies may distinguish between these 
putative mechanisms and determine the effect of the eliciting genotoxin on TLS Pol 
selection. 
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Figure 6-3. Hypothetical models of damage-responsive Y Polymerase selection. 
Cdc7-mediated Rad18 phosphorylation promotes Rad18 interactions with all 
TLS polymerases equally (A) or specifically with Polh (B). 
 
Specific experiments to address the question of TLS Pol selection should first 
focus on the kinetics of TLS Pol recruitment to sites of DNA damage for different 
genotoxins. Based on the lesion-specific accuracy of Polη and Polκ for bypassing 
UV- and BPDE-induced DNA lesions, respectively, it is logical to hypothesize that 
cells utilize regulated rather than random mechanisms of polymerase selection. 
Specifically, we hypothesize that Polη is recruited to replication forks and engages 
with PCNA preferentially in response to UV-induced damage and that Polκ is 
recruited and engaged preferentially in response to BPDE-induced damage. This 
hypothesis is best tested by a combination of immunoprecipitation of each respective 
TLS Polymerase and PCNA at increasing timepoints after DNA damage and 
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immunofluorescent microscopy of chromophore-tagged polymerases at similar 
timepoints. These experiments will help determine how the TLS Pols are recruited to 
stalled replication forks and what mechanisms regulate this process. 
Next one should determine whether Cdc7 regulates recruitment of Polκ to 
stalled replication forks and its subsequent bypass of BPDE-induced lesions. UV 
damage-induced phosphorylation of Rad18 by Cdc7 facilitates binding of Rad18 and 
Polη, an interaction we hypothesize is necessary for bypass of CPDs (the lesion 
caused by UV). Rad18 also binds to Polκ in a similar damage-responsive manner, due 
to BPDE rather than UV, and perturbation of Rad18-Polκ binding (by Rad18 or Polκ 
depletion) impairs recovery from the BPDE-induced S-phase checkpoint.141,235 But 
the impact of Cdc7 signaling on Rad18 and Polκ interactions has never been 
investigated. Based on the role of Cdc7 in facilitating tolerance of UV-induced CPDs 
by Polη, it is logical to hypothesize that Cdc7 mediates BPDE-responsive association 
between Rad18 and Polκ and loss of Cdc7 will impair bypass of BPDE DNA adducts. 
Such a hypothesis may be tested by first determining whether BPDE-inducible Polκ 
and Rad18 binding is Cdc7-dependent via co-immunoprecipitation of Rad18 and Polκ 
after depletion of Cdc7. Measurement of Polκ recruitment to stalled replication forks 
after Cdc7 depletion by immunofluorescence and analysis of recovery from the 
BPDE-induced S-phase checkpoint in the presence or absence of Cdc7 will reveal the 
phenotypic impact of putative Cdc7-dependent Rad18-Polκ interactions. The latter 
should be performed via measurement of the BPDE sensitivity of Cdc7-depleted cells 
treated with increasing doses of BPDE and via 3H-thymidine incorporation assays. 
Together, these experiments will determine whether Cdc7 regulates Rad18-Polκ 
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binding and Polκ-mediated bypass of BPDE-induced DNA damage. Combined with 
the kinetic assays above, these studies will help determine the mechanisms that 
dictate selection of the proper TLS Polymerase for the appropriate DNA lesion. 
 
1.4. Endogenous Impediments to Normal Replication  
In addition to the DNA adducts caused by common environmental genotoxins, 
many naturally occurring aberrant DNA structures also interfere with normal DNA 
replication.236 One such replication-blocking structure is G4 (or G-quadruplex) DNA, 
which naturally develops in guanine-rich stretches of DNA. In G4 DNA, four 
guanines are arranged in a hydrogen bond-stabilized ring around a mono-valent 
cation (Figure 6-4).237 These guanine rings are planar and stack on top of each other 
to form extremely stable structures involving one to four strands of DNA; most 
endogenous G4 structures in cells are single-stranded.238 Due in part to the high 
propensity of many natural sequences in the human genome to form G-quadruplex 
DNA (estimated at over 300,000 sequences),239 G4 DNA has been implicated in 
many biological functions, such as transcriptional regulation and telomere 
maintenance and protection.237, 240 Notably, G4 structures have been identified in 
several important oncogene promoters, such as c-Myc,241 KRAS242, and c-KIT,243 and 
the presence of G4 structures in telomeres has been known for over two 
decades.244,245 
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Figure 6-4. Schematic of G4 DNA.  
A planar quartet of guanines surrounding a cation (usually potassium) and the 
stacking of these quartets to form a 3-dimensional G-quadruplex structure. (image 
modified from Qin, 2008).  
 
 
Importantly, because normal and G4 DNA differ so dramatically in both 
structure and stability, most DNA metabolizing enzymes are incapable of properly 
processing G4 DNA.237 Few specialized enzymes that can process G4 DNA have 
been identified, and defective G4-processing by specialized helicases capable of 
unwinding G4 DNA has been targeted as potential contributing factors in 
chromosomal instability syndromes, such as Werner Syndrome (WRN protein),246 
Bloom’s Syndrome (BLM protein),247 and Fanconi Anemia (FancJ protein).248 The 
consistent presence of G4 DNA in telomeres and the observation that loss of the G4-
unwinding helicase activity of WRN protein leads to elevated homologous 
recombination specifically at telomeres249 has lead to the hypothesis that improper 
processing of G4 DNA may contribute genetic instability.250,251 
It is thus of great importance to understand the mechanisms utilized by cells to 
tolerate G4 DNA, yet it is largely unknown how G4 structures are processed during 
important functions such as DNA replication and transcription. It has been shown that 
TLS polymerase-depleted human cells are sensitized to agents that stabilize G4 DNA 
and that G4 DNA is a natural substrate of Polη and Polκ.232,252 However, the impact 
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of important players in the TLS pathway, such as Rad18, PCNA, and Chk1, has not 
been studied in this context. Does Polη and Polκ activity in processing G4 structures 
depend on Rad18? Does PCNA ubiquitination help facilitate tolerance of G4 DNA? 
Does loss of TLS enzymes, such as Rad18, Polη, and Polκ, sensitize cells to killing 
by G4-stabilizing compounds? 
Preliminary studies have shown that cells treated with the G4 stabilizing 
substances, such as telomestatin, exhibit prolonged Chk1 phosphorylation and PCNA 
monoubiquitination, suggesting a role for checkpoints and TLS in tolerance of G4 
DNA. Future studies should test the hypothesis that mis-regulated TLS contributes to 
genomic instability due to improper bypass/processing of G4 DNA, in particular at 
telomeres. These experiments may compare how the same damage tolerance 
mechanism (TLS) is activated differently in response to environmental (UV, BPDE) 
or endogenous (G4) obstacles to replication. For instance, as shown in Chapter 4, 
TLS activation depends on checkpoint signaling; is this the same for G4-targeted 
activation of TLS? Experimentally, does depletion of Chk1 reduce telomestatin-
induced redistribution of TLS polymerases? Such studies will shed light on the 
mechanisms used by cells to direct damage tolerance by TLS toward endogenous or 
environmentally induced obstacles to replication. 
Specifically, it is of interest to test the hypothesis that Rad18 confers bypass 
of G-quadrupled DNA. Thousands of stretches of genomic DNA are capable of 
adopting G4 conformation, including promoters in clinically relevant oncogenes and 
in telomeres.250 Although helicases capable of unwinding G4 DNA have been 
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identified, it is unknown how cells maintain normal replication after encountering G4 
structures. Recent work implicates Polη and Polκ in processing G4 DNA.232 Because 
of the known functions of Rad18 in facilitating the activity of Polη and Polκ, we 
hypothesize that Rad18 is also involved (Figure 6-5). Telomestatin is a natural 
product first isolated in 2001253 that has been shown to intercalate between the planar 
guanine quartets to stabilize G-quadruplex DNA with an extremely high specificity 
and potency.254 We thus hypothesize that cells depleted of Rad18 will be sensitized to 
killing by G4-stabilizing agents such as telomestatin.  
 
Figure 6-5. Potential function of Rad18 in facilitating Polη and Polκ-mediated processing of G4 
DNA. 
  
 
Next, based on the novel non-catalytic function of Polη demonstrated in 
Chapter 2 that demonstrates a role for Polη in stimulating Rad18-mediated PCNA 
monoubiquitination, we would hypothesize that Polη impacts the activity of Rad18 at 
G4 DNA. Experimentally, this hypothesis is tested by measuring whether 
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telomestatin-induced chromatin association of Rad18 is compromised in Polh 
depleted cells. 
Together, these studies will determine whether Rad18 mediates tolerance of 
G4 DNA, thus defining a novel mechanism through which TLS mediates tolerance of 
aberrant DNA structures. 
 
2. Conclusions 
The results presented in this dissertation define new regulatory aspects of TLS 
that were previously unknown. First, Chapter 3 demonstrates that Polη, previously 
recognized as a Translesion DNA polymerase with one sole effector function, that of 
a polymerase, in fact performs an additional function that is entirely independent of 
is catalytic activity. This function serves to facilitate physical interacts between 
Rad18 and its ubiquitination target, PCNA, and thus stimulate TLS via PCNA 
monoubiquitination. Identification of this catalytic-independent function of Polη has 
important implications for the molecular basis on which mutagenesis is thought to 
develop in XPV cells, as well as any cell in which Polη function or expression may 
be altered. Additionally, because so many other DNA damage tolerance pathways 
depend on PCNA monoubiquitination (eg template switching, instrastrand cross-link 
repair, Fanconi Anemia), Polη expression is likely to impact numerous other aspects 
of the cellular DNA damage response.  
Next, Chapter 4 demonstrates a novel role for checkpoint signaling that 
directly contributes to the regulation of TLS via promoting interaction between 
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Rad18 and Polη. This finding builds on the Polη-induced monoubiquitination of 
PCNA demonstrated in Chapter 3, such that loss of Chk1 signaling abrogates Rad18-
Polη binding and in turn compromises PCNA monoubiquitination. Additionally, the 
results shown in Chapter 4 reveal a novel link between stress kinase signaling and 
TLS, such that JNK-mediated phosphorylation of Rad18 contributes to UV-induced 
PCNA monoubiquitination and TLS activation. Together, the results shown in this 
chapter demonstrate cross-talk between different DNA damage response pathways 
and illustrate how cells coordinate various mechanisms to promote genetic stability. 
Finally, Chapter 5 presents data that reveal a novel relationship between TLS 
and oncogenic signaling. Oncogenes have been known to cause replication stress, 
activate a DNA damage response, and eventually induce cellular senescence. 
However, the mechanisms by which cells tolerate such oncogenic stresses have 
remained poorly understood. Our findings reveal that TLS contributes to cellular 
tolerance of oncogene-induced replication stress. Not only does expression of certain 
oncogenes lead to a robust activation of TLS, as indicated by PCNA 
monoubiquitination and mobilization of Rad18 and Polη, but loss of TLS effector 
proteins Rad18 and Polη compromises the survival of cells expressing oncogenes. 
We therefore conclude that TLS proves a cellular mechanism of tolerating 
oncogene-induced replication stress. This conclusion is further supported by the 
findings that lung neoplasms express abnormally high levels of Rad18 and that loss 
of Rad18 dramatically changes the growth and progression of Ras-induced lung 
tumors in vivo. 
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Altogether, it is hoped that the findings presented in this dissertation will help 
address some of the remaining unknowns in the field of genome maintenance and 
tumorigenesis. Specifically, this dissertation shows that Polη contributes to genome 
stability via polymerase-independent functions and that TLS contributes to tolerance 
of oncogene-induced replication stress. These novel findings help explain how TLS 
contributes to genome maintenance and may help guide the development of 
antiproliferative therapies. For example, consistent with the survival results shown in 
Figure 5-4, can inhibition of TLS reduce the survival of malignant cells in vivo? Or, 
consistent with the role for catalytically-dead Polη in promoting mutagenesis 
(Chapter 3), would XPV patients harboring full-length, catalytically inactive Polη 
have a better prognosis if the Rad18-stimulatory function of their mutant Polη were 
blocked? The author hopes that these and other questions stemming from this 
research will advance our understanding of molecular carcinogenesis and eventually 
translate to better treatment for and survival of people afflicted with cancer. 
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